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Abstract 
 Sudden cardiac arrest (SCA) is one of the leading causes of death in the 
United States. While several risk factors are observationally associated with SCA, 
the genetic architecture of SCA in the general population remains unknown.  
Furthermore, understanding which risk factors are causal may help target 
prevention strategies. Given that SCA is a complex disease with a heterogeneous 
makeup of risk factors and underlying causal diseases that may differ by both race 
and sex, studying the genetics of this disease has proved challenging. Here, we 
use genome-wide association studies (GWAS) to identify common genetic 
variants associated with SCA risk. We performed race-, sex-, and disease-
stratified GWASs in an attempt to create a more homogenous phenotype in order 
to identify variants associated with SCA risk. However, we were not able to 
identify any common genetic variants associated with SCA. 
We utilized Mendelian randomization to identify causal risk factors for 
SCA, identifying CAD status, BMI and QT interval as being causally associated.  
We further investigated the genetic association between prolonged QT interval 
and SCA risk in sex-stratified and disease-stratified (ischemic vs. non-ischemic 
disease) analyses. We tested for association between the top QT interval 
associated SNP, rs12143842 (in the NOS1AP locus), and SCA risk. We also 
tested for causal association of QT interval in the various subgroups. We found 
that non-ischemic individuals, particularly women with non-ischemic disease, 
showed the strongest association between rs12143842 and SCA risk and the 
strongest causal association. Ischemic SCA victims, irrespective of sex, did not 
	 iii 
show an association between rs12143842 and SCA risk or a causal association for 
QT interval. 
This work sought to further our understanding of the genetics of SCA and 
its underlying etiology. While we were not able to identify any common genetic 
variants associated with SCA, we did identity several causal risk factors for SCA 
and found these causal risk factors may differ by both underlying disease and sex. 
Furthering our knowledge of the genetics of SCA, its etiology, and its causes will 
ultimately lead to better identification of higher risk individuals. 
 Advisor: Dan E. Arking, Ph.D. 
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Chapter 1: Introduction 
 
 
Sudden cardiac arrest (SCA) is a major public health concern, affecting 
 
~300,000 individuals in the US every year.1 While there are many different 
definitions of SCA, the American Heart Association defines SCA as “unexpected 
cessation of cardiac mechanical activity, as confirmed by the absence of signs of 
circulation.”1 SCA is commonly the result of ventricular fibrillation and is often 
the first manifestation of heart disease.2,3 Currently, the biggest risk factor for 
SCA is reduced ejection fraction (EF). The ejection fraction is the percentage of 
blood that is pumped out of the left ventricle with each heartbeat. Normal EF 
ranges from 50-65% and reduced EF is generally considered to be less than 35%.4 
A meta-analysis of twenty different studies found that an EF <30% to <40% was 
associated with a relative risk of 4.3 for major arrhythmic events.5 However, 
given the majority of individuals who have an SCA event have a normal ejection 
fraction, the utility of EF as a predictor for SCA is highly limited. In addition, 
observational studies have identified numerous other clinical and subclinical risk 
factors for SCA; understanding which of these associations are causal will help 
target prevention strategies. Identifying individuals at increased risk for SCA, as 
well as finding preventative and therapeutic measures, is necessary to reduce the 
impact of this largely fatal disease. 
Several studies have identified family history of SCA as a strong predictor 
of SCA in the general population, suggesting that genetic variation may influence 
SCA risk. One study found that a family history of SCA (<65 years of age) was 
associated with 2.7-fold increased risk for SCA after adjusting for history of MI 
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and other CVD risk factors.6 The Paris Prospective study of ~7,000 individuals 
found a history of one parent with an SCA event was associated with a relative 
risk of 1.89 of developing SCA and a history of both parents with an SCA event 
was associated with a relative risk of 9.44 of developing SCA.7 Identifying 
genetic markers associated with SCA risk could provide additional risk 
stratification beyond the traditional risk factors mentioned above. 
However, identifying genetic variation associated with SCA risk has 
proven to be difficult and the findings have been mixed. Studies first utilized 
candidate gene approaches, investigating SNPs within genes that are known to be 
associated with SCA in individuals with different inherited arrhythmia conditions 
such as Long QT Syndrome and Brugada Syndrome. Smaller studies have found 
both rare and common variants within these genes associated with SCA risk in the 
general population.8–11 However, we recently published a large study (3,939 cases 
and 25,989 controls) in which we did not find evidence that common variation in 
Mendelian arrhythmia genes is associated with SCA risk in the general 
population.12 
To expand the search for common genetic variants associated with SCA 
outside of known arrhythmia genes, our lab previously published the first 
genome-wide association study (GWAS) of individuals of European descent 
consisting of 1,283 SCA cases and >20,000 controls.8 One SNP within the BAZ2B 
gene reached the genome-wide significance threshold (5x10-8). However, we 
recently published a larger GWAS of European descent individuals, consisting of 
3,939 SCA cases and 25,989 controls, which did not replicate this finding.12 
Further, we failed to identify any variant that reached the genome-wide 
significance threshold (P<5x10-8). In addition to the lack of power, the 
heterogeneity of the SCA phenotype may also cause the failure to replicate the 
previous findings and lead to the lack of additional findings. 
SCA occurs as a result of multiple underlying disease pathologies, 
including heart diseases such as coronary artery disease (CAD) and 
cardiomyopathies, as well as primary electrical defects.13 Men have a higher risk 
of SCA than women14,15, and furthermore, the underlying cardiac pathology 
 
differs between the sexes. CAD, the common underlying cause of SCA, is more 
common in men than women. By contrast, non-ischemic pathology, such as 
primary myocardial fibrosis, valvular heart disease, and arrhythmogenic right 
ventricular cardiomyopathy, occurs more commonly in women with SCA 
compared to men with SCA.16–18 Given these known differences, it can be 
hypothesized that risk factors, in addition to genomic markers, associated with 
SCA may differ between both the underlying causal disease and sex. 
The results of our two genome-wide association studies may provide 
evidence for this hypothesis. The first GWAS for SCA of 1,283 cases and 
>20,000 controls included almost exclusively SCA individuals with underlying 
CAD from 5 different studies, given the majority of the studies explicitly  
excluded SCA cases with non-ischemic underlying disease. The second GWAS of 
3,939 cases and 25,989 controls included SCA individuals from 9 different  
studies in which studies did not exclude cases with non-ischemic disease, such as 
valvular heart disease and cardiomyopathy. While the second GWAS had a larger 
sample size, the additional cases of different underlying disease may be 
contributing to lack of findings if the associated genetic variation with SCA risk 
differs by underlying disease. Previously, stratifying cases in genome-wide 
analyses of complex diseases by subtype or risk factor have been successful in 
identifying genetic variants specific to the subgroups. Some of these stratified 
analyses include: ischemic stroke stratified by cases with different pathologies 
(cardioembolic, small vessel and large vessel)19; migraine stratified by cases with 
 
and without aura20; type 2 diabetes stratified by BMI of cases21; and rheumatoid 
arthritis stratified by the presence or absence of antibodies to citrullinated peptide 
antigens (ACPA)22. Therefore, we hypothesize that stratifying SCA cases by 
underlying disease may create a more homogenous SCA phenotype and increase 
our ability to detect genetic variants associated with SCA risk in these subgroups 
and the associated genetic variants may differ between the subgroups. 
In addition to underlying disease and sex, SCA risk also differs by race. 
Studies have found African Americans are disproportionately affected by SCA in 
every age group.23–25 There are likely several factors contributing to this increased 
risk. African American individuals have higher rates of traditional cardiac risk 
factors, including hypertension26, left ventricular hypertrophy27, heart failure, 
obesity and type 2 diabetes.28 These higher rates of cardiac risk factors and SCA 
may also be a result of large racial disparities in health care; one study found that 
African Americans are more likely to not survive an in-hospital cardiac arrest 
compared to Caucasians, indicating the lower survival rate among African 
Americans may be due to the quality of care they receive at a specific medical 
center.29 African American individuals are also less likely to receive an 
implantable cardioverter defibrillator (ICD) for primary prevention of SCA.30 
While these factors all likely contribute to the racial differences in SCA risk, we 
wanted to examine whether genetics plays a role in the differences as well. Given 
no GWAS for SCA has ever been performed in African American individuals, it 
is unknown whether the genetic markers associated with SCA risk would differ 
between races. 
All of these factors, race, sex and underlying disease, have contributed to 
the difficulty in studying the genetics of SCA. Given our null results from a 
GWAS of relatively large sample size, there is evidence that there are no common 
genetic variants of large effect associated with overall SCA risk in the European 
population. However, we hope to identify genetic variants of moderate or lower 
effect on SCA risk by increasing the sample size of the European ancestry  
GWAS. We also performed sex-stratified GWAS for individuals of European 
descent. In addition, we performed a GWAS for SCA in African American 
individuals for the first time, to identify any genetic markers associated with SCA. 
Finally, we utilized a large Finnish study of SCA individuals with post-mortem 
autopsy-confirmed underlying disease to study the disease-specific (ischemic vs. 
non-ischemic disease) genetic variants associated with SCA risk. 
To identify causal traits of SCA, we performed Mendelian randomization, 
 
a method utilizing associated genetic variants with known SCA risk factors. 
Lastly, we utilized our large Finnish study of post-mortem autopsy-confirmed 
SCA individuals to stratify by underlying causal disease (ischemic vs. non- 
ischemic disease) and sex to study the differences in causal risk factors with SCA 
between these different groups. Overall, our goal was to further our knowledge of 
the genetics of SCA and better understand it’s underlying etiology. 




Race appears to play a significant role in the development of SCA; studies 
have found individuals of African descent have a higher risk of SCA than 
individuals of European descent.28,31 There are also large racial disparities in 
cardiac health care and higher rates of traditional cardiac risk factors among 
African Americans that could also lend to the observed increased rates of SCA. 
While these health disparities do lead to the increased risk of SCA 
observed in the African American population, there is also some evidence that 
genetic variation may also lead to increased risk. Studies have found differences 
between ethnicities in allele frequency for encoding sodium and potassium 
channels which are associated with J-point elevation, Brugada syndrome, and 
Long QT syndrome.28 However, there is also evidence that the specific genetic 
variants associated with SCA risk may be shared among the different ethnicities, 
although the allele frequency and effect size may differ. For example, a QT 
interval GWAS in African American individuals found the NOS1AP locus SNP 
rs12143842, a SNP also previously found to be associated with SCA risk, as the 
top QT interval-associated SNP.32 This is the same top QT interval-associated 
SNP found in the QT interval GWAS in European individuals.33 It is likely that 
there is both race-specific and non-race specific genetic variation associated with 
SCA risk. 
Given that men have a higher risk of SCA than women14,15 and the 
underlying causal disease differ by sex, in addition to race, genetic variation 
associated with SCA risk may also differ by underlying disease pathology and 
sex. Genome-wide association studies (GWAS) are a useful tool to identify 
common genetic variation associated with SCA risk. Identifying genomic risk 
markers for SCA will help classify those individuals at high risk in the general 
population. Previously, we performed a GWAS for SCA in European-descent 
individuals using 3,939 SCA cases and 25,989 controls to identify potential 
genetic variation associated with SCA risk.12 However, no SNP reached the 
genome-wide significance threshold (P<5x10-8). Here, we ran a GWAS for SCA 
using individuals of European descent with an additional 1,351 SCA cases and 
1,008 controls (a total of 5,290 SCA cases and 26,997 controls), as well as a sex- 
stratified GWAS. We also ran a GWAS for SCA using African American 
individuals (974 SCA cases and 3,526 controls). Finally, we performed a trans- 
ethnic GWAS for SCA using European (5,290 SCA cases/26,997 controls), 
African American (974 SCA cases/3,526 controls), and Asian (152 SCA 
cases/176 controls) individuals for a total of 6,416 SCA cases and 30,699 
controls. 
In addition to perform race-specific GWASs, we also stratified by 
underlying disease. We used a large Finnish study of individuals who died from 
an SCA event with a post-mortem autopsy that confirmed the underlying causal 
disease (ischemic vs. non-ischemic) as well as Finnish population controls. We 
hypothesized that there are genetic differences between those individuals with 
diagnosed CAD and individuals with CAD whom go on to have an SCA event. 
To test this hypothesis, we used two control cohorts of individuals with diagnosed 
CAD to perform the GWAS. Finally, we stratified by underlying disease 
pathology in order to create a more homogenous phenotype that may result in the 
improved ability to detect genetic variants associated with SCA risk. 
2.2 Methods 
 
2.2.1 Study Population and Phenotype Definition 
 
2.2.1a Race-stratified and trans-ethnic analyses 
 
We conducted a GWAS for individuals of European descent using 9 
studies consisting of 5,290 SCA cases and 26,997 controls. We also conducted a 
GWAS for individuals of African descent using four different studies consisting 
of 974 SCA cases and 3,526 controls. Finally, we performed a trans-ethnic 
GWAS consisting of the studies of individuals of European descent, African 
American descent, as well as one study of individuals of Asian descent (152 SCA 
cases and 176 controls) for a total of 6,416 SCA cases and 30,699 controls. Study 
descriptions, study-specific SCA definitions and genotyping methods are detailed 
in Table 2.1 and 2.2. 
2.2.1b Underlying causal disease stratified analyses 
Fingesture 
The Fingesture study, started in 1998, aimed to collect consecutive victims 
of out-of-hospital sudden death from a defined geographical area, Oulu University 
Hospital District in northern Finland. All victims of sudden death were autopsied 
at the Department of Forensic Medicine, University of Oulu, Oulu, Finland. SCA 
victims were defined as those with a witnessed sudden death within 6 hours of the 
onset of the symptoms or within 24 hours of the time that the victim was last seen 
alive in a normal state of health. Individuals with age at SCA event <30 years old 
or >80 years old were excluded from analysis. 
The underlying pathologies were divided into three categories: (1) 
ischemic, (2) non- ischemic, and (3) other disease. The ischemic SCA victims 
included individuals with evidence of a coronary complication, defined as a fresh 
intracoronary thrombus, plaque rupture or erosion, intraplaque hemorrhage, or 
critical coronary stenosis (>75%) in the main coronary artery. The non-ischemic 
SCA victims included individuals with the following conditions: hypertrophy due 
to hypertension; valve disease; cardiomyopathy due to alcohol use; dilated 
cardiomyopathy; hypertrophic obstructive cardiomyopathy; cardiomyopathy due 
to obesity; arrhythmogenic right ventricular cardiomyopathy; and primary 
myocardial fibrosis. Further definitions of these conditions have been previously 
described.16 The “other” SCA victims included individuals with the following 
conditions: myocarditis, cardiac anomaly, and normal autopsy individuals (e.g. 
individuals with a channelopathy). 
NFBC1966 
 
The Northern Finland Birth Cohort (NFBC) study is the product of a 
project initiated in the 1960s to examine risk factors involved in pre-term birth 
and intrauterine growth retardation, and the consequences of these early adverse 
outcomes on subsequent morbidity. The NFBC1966 cohort comprised of 12,068 
mothers and 12,231 children with an expected date of birth in 1966 within the 
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province of Oulu, Finland. Our study samples consisted of DNA extracted from 
the blood of the offspring at their 31-year follow-up visit. 
Artemis 
 
ARTEMIS is a prospective observational study (Innovation to Reduce 
Cardiovascular Complications of Diabetes at the Intersection; ClinicalTrials.gov 
identifier NCT01426685) that recruited patients with angiographically 
documented CAD, with or without type 2 diabetes. The study population was 
recruited from a series of patients enrolled in the coronary angiography registry at 
the Division of Cardiology, Oulu University Hospital, between August 1, 2007 
and December 31, 2012. The initial examinations and determination of 
inclusion/exclusion status were conducted at least 3 months after coronary 
angiography and/or the last revascularization.34 
MRFAT 
 
The Multiple Risk Factor Analysis Trial (MRFAT) study population 
consisted of enrollees in a prospective post-MI study, enrolled between January 
1996 and January 2000. The diagnosis of MI was based on the presence of at least 
two of three criteria from ICD-10: elevated troponin levels, ECG findings, and 
typical angina pectoris. 
2.2.2 GWAS 
 
For the European studies, genome-wide genotype data was imputed to 
either the HapMap2-CEU reference panel or the TOPMed Freeze 5 reference 
panel. Studies that provided sex-stratified data were utilized in the sex-specific 
GWAS meta-analysis as indicated in Table 2.1. Genome-wide genotype data for 
11
the African American studies was imputed to the TOPMed Freeze 5 reference 
panel. Genome-wide genotype data for the study of individuals of Asian descent 
was imputed to 1000G Phase1v3. Each study performed regression analyses 
adjusting for sex and other study-specific covariates. Inverse variance meta- 
analysis using METAL35 was performed for the European-only and African 
American-only meta-analyses. For the European-only GWAS, a SNP had to 
present in at least 4/10 of the studies to be included in the final analysis. 
The trans-ethnic meta-analysis was performed using the software  
Metasoft. Metasoft uses three different meta-analysis methods: (1) fixed effect 
model; (2) random effects model; and (3) Han and Eskin's random effects  
model.36 The third model, Han and Eskin’s random effects model, differs from the 
traditional random effects model in that it assumes no heterogeneity under the null 
hypothesis. Therefore, in the presence of heterogeneity, this model is more 
powerful than the traditional random effects model. A SNP had to be present in at 
least 4/16 of the studies to be included in the final analysis. 
The underlying disease stratified GWASs were performed using 1,171 
Fingesture (614 ischemic and 557 non-ischemic) SCA individuals; 761 population 
controls (NFBC1966); and 1,015 ischemic controls (455 Artemis and 560 
MRFAT). Samples were run on either the Illumina Infinium Global Screening 
Array (GSA) or the Affymetrix Genome-wide Human SNP Array 6.0 and  
imputed to the TOPMed Freeze 5 reference panel. Three different analyses were 
performed: ischemic SCA individuals vs. population controls; ischemic SCA 
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individuals vs. ischemic controls; and non-ischemic individuals vs. population 
controls. We performed logistic regression using FASTv2.4.37 
2.3 Results 
 
2.3.1 Race-specific GWAS 
 
After meta-analysis of the nine studies of individuals of European descent 
(5,290 SCA cases and 26,997 controls), no SNP reached genome-wide 
significance (5x10-8). In addition, no SNP reach genome-wide significance for the 
meta-analysis of the four studies of individuals of African American descent (974 
SCA cases and 3,526 controls). The QQ plot and Manhattan plot for these race- 
specific meta-analyses are shown in Figures 2.1 and 2.2, respectively. 
2.3.2 Trans-ethnic GWAS 
 
There were no SNPs that reached the genome-wide significance threshold 
under the fixed effects and traditional random effects models. One SNP, 
rs10803352, reached genome-wide significance using the Han and Eskin's 
random effects model. The QQ plots and Manhattan plots for these meta-analyses 
are shown in Figures 2.3 and 2.4, respectively. The forest plot for the top SNP 
(rs10803352) is shown in Figure 2.5. However, while the SNP achieved genome- 
wide significance, it is clear the association is driven by one of the studies. Given 
this association is not replicated in the other studies, this is likely a false positive 
association, and therefore we concluded that no true positive SNP reached the 
genome-wide significance threshold for meta-analysis using the Han and Eskin's 
random effects model. 
1
2.3.3 Sex-specific GWAS 
 
Neither the men nor women-specific GWAS had SNPs that reached the 
genome-wide significance threshold. The QQ plots and Manhattan plots for these 
meta-analyses are shown in Figures 2.6 and 2.7. 
2.3.4 Disease-specific GWAS 
 
None of the disease-specific GWASs identified any SNP associated with 
SCA risk at the genome-wide significance threshold. QQ plots and Manhattan 
plots are shown in Figures 2.8 and 2.9. However, the top SNP from each GWAS 
(ischemic cases/population controls; ischemic cases/ischemic controls; non- 
ischemic cases/population controls) were unique to each GWAS. Regression 
results for each top SNP in all analyses are found in Tables 2.3 (ischemic 
cases/population controls), Table 2.4 (non-ischemic cases/population controls), 
and Table 2.5 (ischemic cases/ischemic controls). 
2.4 Discussion 
 
SCA is a complex disease with a heterogeneous make-up of risk factors 
and underlying causal diseases. This heterogeneous nature contributes to the 
difficulty in identifying genetic markers associated with SCA risk. Our previous 
attempt to identify common genetic variation associated with SCA risk in 
individuals of European descent using the largest GWAS (3,939 cases and 25,989 
controls) failed to identify any SNP of genome-wide significance.38 Here, with the 
addition of new European SCA cases and controls, while we did identify SNPs of 
greater significance than the previous study, we still failed to identify any 
common genetic variation associated with SCA risk that exceeded the genome- 
1
wide significance threshold in individuals of European descent. We also 
performed the largest GWAS to date for SCA risk using African American 
individuals. Similar to the European GWAS, we were unable to identify any SNPs 
that reach genome-wide significance. 
In the trans-ethnic GWAS, even when utilizing different statistical models, 
we were unable to identify any plausible SNPs associated with SCA risk. While 
the Han and Eskin’s random effects model found one SNP that exceeded the 
genome-wide significance threshold, it was largely driven by one study of African 
American individuals, and therefore likely a false positive finding. This SNP also 
did not replicate in the African American GWAS, lending additional evidence this 
is a false positive. 
Failure to identify any associated SNPs could be due to several different 
factors. First, the SCA phenotype is broadly defined and each study classifies 
SCA somewhat differently. This phenotypic heterogeneity could potentially 
contribute to differences in the underlying genetics; therefore, any SNPs  
identified through this GWAS will have to be the shared risk variants across the 
different SCA phenotypes. Identifying the underlying disease of SCA individuals 
and analyzing the different diseases separately would provide a more homogenous 
phenotype and the ability to identify genetic variants associated with SCA risk 
within that phenotype. Second, the genetic susceptibility to SCA may be derived 
of multiple variants of moderate or low effect size and therefore our sample size is 
not large enough to detect these effect sizes. Given that the African American 
GWAS has fewer than 1,000 SCA cases, a lack of power is likely a major factor 
1
in the failure to identify genome-wide significant SNPs for that particular racial 
group. Additional samples would assist in increasing power to detect these 
variants of moderate and lower effect sizes. Third, the causal SNP(s) may not be 
available in the earlier reference panels used in the imputation of most of the 
studies. Recently, the TOPMed reference panel became available for use with 
imputation. We were able to use it for imputation for 6 of the 16 studies used in 
the various meta-analyses. The TOPMed reference panel provides significantly 
more SNPs (>7 million post QC) than older reference panels (typically ~2 million 
SNPs). Updating the other studies to imputation using the TOPMed reference 
panel would provide analyses on a significantly larger number of SNPs, 
increasing the power to detect associations with these SNPs. All of these 
limitations likely contribute to the lack of genome-wide significant SNPs 
associated with SCA risk in our three GWASs. 
In conclusion, we did not identify any genome-wide significant SNPs in 
any of our analyses, likely due to lack of power and phenotypic heterogeneity. 
However, when stratifying by underlying causal disease, we did see more 
significant results and the top SNPs were unique to each disease subtype, 
indicating the genetic variation influencing SCA risk is likely specific to each 
underlying disease. Including new SCA cases, as well as identifying the 
underlying causal disease in order to create a more homogenous phenotype in the 
existing studies, and imputing all data to the TOPMed reference panel are all 
ways to improve potential detection of common genetic variants associated with 
SCA risk. Ultimately, identifying genetic risk markers for SCA will improve 
1




Figure 2.1: QQ plots for race-specific GWASs for SCA 
 








Figure 2.2: Manhattan plots showing results for race-specific GWASs for 
SCA 












Figure 2.3: QQ plots for trans-ethnic GWAS for SCA 
 
A. Fixed effects model 
 
 









Figure 2.4: Manhattan plots showing results for trans-ethnic GWAS for SCA 
 
A. Fixed effects model 
 
 





C. Han and Eskin's random effects model 
 
 





The forest plot for the single SNP (rs10803352) that reached the genome-wide 
significance threshold using the Han and Eskin's random effects model shows the 
significance of the SNP is largely driven by a single cohort (MEG_MEGA.AA). 
Given the effect is not replicated in the other cohorts, this SNP is likely a false 
positive finding. 




















Figure 2.8: QQ plots for the disease-stratified GWASs 
 
A. Ischemic cases/Population controls 
 
 




C. Ischemic cases/Ischemic controls 
 
 
Figure 2.9: Manhattan plots for the disease-specific GWASs 
 





B. Non-ischemic cases/Population controls 
 
 







Table2.1 Sample Characteristics of European Cohorts 
Cohort ARIC CABS CARTAGENE 
N, number of cases with genotype data 204 2165 166 
N, number of controls with genotype data 8,682 2430 241 





QC criteria, per sample 
Sex-check, Removed 
duplicates, checks for cryptic 
relatedness and genetic 
outliers from PCA 
Sex-check, Removed 
duplicates, checks for cryptic 
relatedness and genetic 
outliers from PCA 
Sex-check, Removed 
duplicates, checks for 
genetic outliers from 
PCA 
Genotyping platform Affymetrix 6.0 Affymetrix Axiom Illumina Human660K 
Genotype calling algorithm Birdseed apt-probeset-genotype Illumina beadstudio 
Inclusion criteria--MAF >1% >1% >=1% 
Inclusion criteria--Call Rate per SNP >95% >95% >=95% 
Inclusion criteria--pvalue HWE >1E-4 >1E-5 >=5E-6 
Autosomal SNPs after QC 7,300,831 2,543,888 2,599,339 
Imputation Reference Panel TOPMed Freeze5 Hapmap.v2 Hapmap.v2 
Imputation Software Minimac3 Beagle Impute v1.0.0 
Meta analysis Imputation quality filter >0.75 <1.1 <1.1 








Genomic inflation factor for meta-analysis No adjustment 1.049 1.012 
Sex, number of women among cases 53 496 30 
Sex, number of women among controls 4655 537 50 
Age, mean age at baseline among cases 55.78 67.55 56.2 
Age, age-range at baseline among cases 45-65 20-101 22-77 
Age, mean age at time of SCD among cases 68.29 66.65 56.6 
Age, age-range at time of SCD among cases 51.29-79.95 23-96 28-86 
Average time to SCD, yrs  (for prospective studies) 12.5   
Mean followup time, yrs (for prospective studies) 20.3   




Cohort CHS FHS Fingesture CARTAGENE/ KORA F3 
N, number of cases with genotype data 138 32 340 169 
N, number of controls with genotype data 3157 4358 570 338 









Array call rate <95%, 
sex check 
 Sex-check, Removed 
duplicates, checks for 
cryptic relatedness and 
genetic outliers from PCA, 




duplicates, checks for 
















Genotype calling algorithm Illumina beadstudio BRLMM Birdseed Illumina Genomestudio 
Inclusion criteria--MAF >=0% >1% >1% >=0.1% 
Inclusion criteria--Call Rate per SNP >=97% >95% >95% >=98% 
Inclusion criteria--pvalue HWE >1E-5 >1E-6 >1E-6 NA 
Autosomal SNPs after QC 2,613,506 2,010,513 7,088,524 560,568 
Imputation Reference Panel Hapmap.v2 Hapmap.v2 TOPMed Freeze5 not imputed 
Imputation Software BimBam Mach Minimac3 not imputed 
Meta analysis Imputation quality filter <1.1 <1.1 & >=0.4 <1.1 not imputed 
Meta analysis minor allele count (MAC) in cases filter >5 >5 >10 >5 
Genomic inflation factor for meta-analysis 1 1.024 1.029 No adjustment 
Sex, number of women among cases 70  52 29 
Sex, number of women among controls 1935  135 58 
Age, mean age at baseline among cases 72.34  63.85 58 
Age, age-range at baseline among cases 64-98  35-92 19-76 
Age, mean age at time of SCD among cases 74.09  61.22 59.5 
Age, age-range at time of SCD among cases 65-94  28-83 35-84 
Average time to SCD, yrs  (for prospective studies) 9.17 3.78   
Mean followup time, yrs (for prospective studies) 12.9 5.56   
Study design Prospective Prospective Case-control Case-control 
 
 
Cohort Harvard Rotterdam study Fingesture 
N, number of cases with genotype data 420 385 1,171 
N, number of controls with genotype data 424 5589 1,208 





QC criteria, per sample 
 
 
Checks for cryptic relatedness 
and genetic outliers from PCA, 
genotyping call rate > 95% 
 
Sex-check, Removed 
duplicates, checks for cryptic 
relatedness and genetic 
outliers from PCA 
Sex-check, Removed 
duplicates, checks for cryptic 
relatedness and genetic outliers 








Illumina Global Screening 
Array 
Genotype calling algorithm Birdseed Beadstudio Genecall Illumina beadstudio 
Inclusion criteria--MAF >1% >1% >1% 
Inclusion criteria--Call Rate per SNP >95% >95% >95% 
Inclusion criteria--pvalue HWE >1E-6 >1E-6 >1E-4 
Autosomal SNPs after QC 2,402,071 2,494,839 9,888,815 
Imputation Reference Panel Hapmap.v2 Hapmap.v2 TOPMed Freeze5 
Imputation Software Mach Mach Minimac3 
Meta analysis Imputation quality filter <1.1 <1.1 & >0.5 NA 








Genomic inflation factor for meta-analysis 1.005 1.029 no adjustment 
Sex, number of women among cases 127 203 420 
Sex, number of women among controls 134 3344 1920 
Age, mean age at baseline among cases 64.3 71.7  
Age, age-range at baseline among cases 40.3-91.9 55.2-95.5  
Age, mean age at time of SCD among cases 64.2 69.3 61.23 
Age, age-range at time of SCD among cases 48.1-96.6 54.5-99.5 35-80 
Average time to SCD, yrs  (for prospective studies) 7.49 9.2  
Mean followup time, yrs (for prospective studies) 11.02 13.2  
 
Study design 
Case-control from prospective 













Sudden, pulseless condition 
from a cardiac origin in a 
previously stable individual, 
review of death and medical 
records 
Sudden, pulseless condition from a 
cardiac origin in a previously stable 
individual, review of death and 
medical records.  Pt in VF or 
asystole (NO PEA) 
Sudden, pulseless condition 
from a cardiac origin in a 
previously stable individual, 
review of death and medical 
records. 
 
Sudden, pulseless condition from 
a cardiac origin in a previously 
stable individual, review of death 













French registry of Acute ST 



















Model with covariates 
 
Cox proportional hazards, with 









age, sex, PCs 






















Sudden pulseless condition 
presumed due to a cardiac 
arrhythmia, without evidence 
for a non-cardiac condition as a 
cause of the arrest, in an 
otherwise stable patient, after 
review of events surrounding 








Coronary heart disease death within 
one hour of onset of symptoms 





Sudden, pulseless condition 
from a cardiac origin in a 
previously stable individual, 
review of death and medical 
records. 
Control definition Population based  MI survivors 






Model with covariates age, sex, clinic age,sex sex, 10 PC 





















a cardiac death is considered a definite SCD if 
the death or cardiac arrest that precipitated 
death occurred within one hour of symptom 
onset as documented by medical records or next 
of-kin reports or had an autopsy consistent with 
SCD (i.e. acute coronary thrombosis or severe 
coronary artery disease without myocardial 






Death <1 hour of cardiovascular 
symptoms or found dead and seen 
<24 hours earliers in stable 
medical condition. Based on 






Sudden, pulseless condition from 
a cardiac origin in a previously 
stable individual, review of death 










Controls from population studies and clinical 
trials matched on on study cohort, sex, age 
(+/−1 year), ethnicity, smoking status (current, 
never, past), time and date of 
blood sampling, fasting status, and presence or 
absence of cardiovascular disease (MI, angina, 

















MI survivors and population 
based 








Model with covariates 20 PCs, cohort age, sex, PCs sex, 10 PC 
Included in sex-stratified meta-analysis Yes Yes Yes 
 
Table 2.2 Sample Characteristics of African American & Asian 
Cohort ARIC CABS CHS 
N, number of cases with genotype data 127 196 29 
N, number of controls with genotype data 1,685 194 686 




QC criteria, per sample 
Sex-check, Removed 
duplicates, checks for cryptic 
relatedness and genetic outliers 
from PCA 
Sex-check, Removed 
duplicates, checks for cryptic 
relatedness and genetic 
outliers from PCA 
 
Sex-check, Removed duplicates, 
checks for cryptic relatedness and 
genetic outliers from PCA 
Genotyping platform Affymetrix 6.0   
Genotype calling algorithm Birdseed   
Inclusion criteria--MAF >1% >1% >1% 
Inclusion criteria--Call Rate per SNP >95% >95% >95% 
Inclusion criteria--pvalue HWE >1E-4   
Autosomal SNPs after QC 6,951,301 8,676,110 7,693,386 
Imputation Reference Panel TOPMed Freeze5 TOPMed Freeze5 TOPMed Freeze5 
Imputation Software Minimac3 Minimac3 Minimac3 
Meta analysis Imputation quality filter >0.75   








Genomic inflation factor for meta-analysis No adjustment 1.045 0.894 
Sex, number of women among cases 63   
Sex, number of women among controls 1076   
Age, mean age at baseline among cases 55.83   
Age, age-range at baseline among cases 46-64   
Age, mean age at time of SCD among cases 67.6   
Age, age-range at time of SCD among cases 48.98-79.84   










Study design Prospective Case-Control Prospective 
 
 
Cohort CVPath/ARIC CABS/CVPath/ARIC CABS-Asian Americans 
N, number of cases with genotype data 187 435 152 
N, number of controls with genotype data 367 593 176 




QC criteria, per sample 
 
Sex-check, Removed duplicates, 
checks for cryptic relatedness and 
genetic outliers from PCA 
Sex-check, Removed 
duplicates, checks for cryptic 
relatedness and genetic outliers 
from PCA 
 
sex check, removed duplicates, 
checks for cryptic relatedness and 









Genotype calling algorithm  Illumina Genomestudio apt-probeset-genotype 
Inclusion criteria--MAF >1% >1% >1% 
Inclusion criteria--Call Rate per SNP >95% >95% >95% 
Inclusion criteria--pvalue HWE >1E-4 >1E-4 >1E-5 
Autosomal SNPs after QC 13,651,803 12,828,867 16820556 
Imputation Reference Panel TOPMed Freeze 5 TOPMed Freeze 5 1000G PhaseIv3 
Imputation Software Minimac3 Minimac3 minimac 
Meta analysis Imputation quality filter >0.75 >0.75 no filter 








Genomic inflation factor for meta-analysis    
Sex, number of women among cases 54 129 70 
Sex, number of women among controls 133 306 91 
Age, mean age at baseline among cases   63.44 
Age, age-range at baseline among cases   20-102 
Age, mean age at time of SCD among cases   61.59 
Age, age-range at time of SCD among cases   32-89 
Average time to SCD, yrs  (for prospective 
studies) 
   
Mean followup time, yrs (for prospective 
studies) 
   
Study design Case-Control Case-Control Case-control 
 
 











condition from a cardiac 
origin in a previously 
stable individual, review 




Sudden, pulseless condition 
from a cardiac origin in a 
previously stable individual, 





Sudden, pulseless condition from a 
cardiac origin in a previously stable 
























Cox proportional hazards, 
















Cox proportional hazards, with age, 
sex, clinic, and PCs as covariates 
 







  Sudden, pulseless condition from a 
cardiac origin in a previously stable 
individual, review of death and 
medical records.  Pt in VF or asystole 
(NO PEA) 
Control definition Population based Population based Population based 
Software used for GWAS statistical analysis FASTv2.4 FASTv2.4 R 
 
 
Model with covariates 
 
Logistic regression with 
sex, PCs1-10 as covariates 
 
Logistic regression with sex, 
PCs1-10 as covariates 
 
 
age, sex, 2 PCs 
 
Table 2.3 Top SNP in ischemic cases/population controls: rs7269951 (C/G) 
 All 
Dataset cases/controls Beta (SE) P-value 
All cases/all controls 1481/1692 -0.301 (0.110) 0.006 
non-ischemic cases/population controls 557/761 -0.508 (0.187) 0.006 
ischemic cases/ischemic controls 1011/952 -0.138 (0.139) 0.32 





Dataset cases/controls Beta (SE) P-value 
All cases/all controls 1368/1250 -0.201 (0.128) 0.10 
non-ischemic cases/population controls 422/354 -0.557 (0.236) 0.02 
ischemic cases/ischemic controls 791/699 -0.063 (0.157) 0.69 
ischemic cases/population controls 531/354 1.03 (0.228) 5.86E-06 
 
 Females 
Dataset cases/controls Beta (SE) P-value 
All cases/all controls 299/871 -0.504 (0.219) 0.02 
non-ischemic cases/population controls 135/407 0.460 (0.302) 0.13 
ischemic cases/ischemic controls 133/232 -0.402 (0.354) 0.26 
ischemic cases/population controls 83/407 -0.706 (0.348) 0.04 
 
Table 2.4 Top SNP in non-ischemic cases/population controls: rs145160360 (C/T) 
 All 
Dataset cases/controls Beta (SE) P-value 
All cases/all controls 1481/1692 0.547 (0.121) 5.77E-06 
non-ischemic cases/population controls 557/761 0.927 (0.182) 3.74E-07 
ischemic cases/ischemic controls 1011/952 0.300 (0.165) 6.90E-02 
ischemic cases/population controls 701/1169 0.425 (0.202) 0.035 
 
 Males 
Dataset cases/controls Beta (SE) P-value 
All cases/all controls 1218/1053 0.521 (0.150) 5.10E-04 
non-ischemic cases/population controls 422/354 1.08 (0.267) 4.90E-05 
ischemic cases/ischemic controls 791/699 0.220 (0.186) 0.88 
ischemic cases/population controls 531/354 0.768 (0.261) 0.003 
 
 Females 
Dataset cases/controls Beta (SE) P-value 
All cases/all controls 268/639 0.601 (0.211) 0.004 
non-ischemic cases/population controls 135/407 0.779 (0.252) 0.002 
ischemic cases/ischemic controls 133/232 0.532 (0.417) 0.32 
ischemic cases/population controls 83/407 -0.351 (0.438) 0.95 
 
Table 2.5 Top SNP in ischemic cases/ischemic controls: rs58823851 (A/G) 
 All 
Dataset cases/controls Beta (SE) P-value 
All cases/all controls 1481/1692 0.224 (0.083) 0.007 
non-ischemic cases/population controls 557/761 -0.252 (0.131) 0.055 
ischemic cases/ischemic controls 1011/952 0.614 (0.116) 1.05E-07 
ischemic cases/population controls 701/1169 0.095 (0.125) 0.45 
 
 Males 
Dataset cases/controls Beta (SE) P-value 
All cases/all controls 1368/1250 0.241 (0.098) 0.013 
non-ischemic cases/population controls 422/354 -0.248 (0.157) 0.12 
ischemic cases/ischemic controls 791/699 0.565 (0.131) 1.66E-05 
ischemic cases/population controls 531/354 0.158 (0.140) 0.26 
 
 Females 
Dataset cases/controls Beta (SE) P-value 
All cases/all controls 299/871 0.133 (0.172) 0.44 
non-ischemic cases/population controls 135/407 -0.251 (0.228) 0.27 
ischemic cases/ischemic controls 133/232 0.800 (0.287) 0.005 
ischemic cases/population controls 83/407 -0.166 (0.290) 0.57 
1
Chapter 3: Identifying causal risk factors for SCA using Mendelian 
Randomization in European Individuals 
3.1 Introduction 
 
Sudden cardiac arrest (SCA) is a major cause of cardiac mortality, 
affecting over 300,000 people in the US every year.39 Despite recent increases in 
SCA survival rates40, survival remains low. Exploring the genomic architecture of 
SCA allows us to assess causal relationships of clinical and subclinical risk 
factors with SCA. Mendelian randomization methods exploit the fact that genetic 
variants are determined at conception and randomly distributed in populations, to 
determine whether an exposure may be causally associated with the outcome, and 
to estimate the effect size of that causal association41–43. 
Here, we use a multi-SNP genetic risk score association (GRSA) model to 
compare genetic associations of 18 known SCA risk factors to genetic 
associations with SCA as an effective way to understand the potential underlying 
causal pathways and processes that modulate SCA risk. While the majority of the 
results reported in this chapter are using the most recently published EA GWAS 
of 3,939 SCA cases and 25,989 controls, we also report the Mendelian 
randomization results for the largest EA GWAS for SCA of 5,290 SCA cases and 
26,997 controls described in the previous chapter, and discuss the discrepancies 
between the two analyses. 
3.2 Methods 
 
3.2.1 Mendelian Randomization Instrument 
Observational studies examine association of an exposure (e.g., body mass 
index, or BMI) with an outcome (e.g., SCA) but cannot assess causality. 
Unobserved variables affecting both exposure and outcome may confound these 
associations and lead to biased estimates of association. Mendelian  
randomization is based on the assumption that because genetic variants are 
determined at conception and are randomly distributed in large populations, they 
are unassociated with potential confounders. Therefore, under certain 
assumptions such as the absence of genetic pleiotropy, genetic variants used as 
instrumental variables can determine whether an exposure is potentially causally 
associated with the outcome, and estimate the size of that association. Here we 
use a multi-SNP genetic risk score association (GRSA) model to compare genetic 
associations with SCA with those of known SCA risk factors as an effective way 
to understand the underlying causal pathways and processes that influence SCA 
risk. 
3.2.2 Genetic Risk Score Association (GRSA) 
 
We estimated a separate GRSA utilizing the recently published SCA 
GWAS of 3,939 cases and 25,989 controls12 for each of the following: (1) CAD 
and traditional CAD risk factors, including type 2 diabetes (T2D), fasting glucose 
adjusted for BMI (FGadjBMI), fasting insulin adjusted for BMI (FIadjBMI), 
diastolic blood pressure (DBP), systolic blood pressure (SBP), total cholesterol 
(TCH), and triglycerides (TG); (2) cardiac electrophysiologic factors, including 
atrial fibrillation (AF), heart rate (HR), QRS interval (QRS), and QT interval 
(QT); and (3) anthropometric traits, including BMI, waist circumference adjusted 
for BMI (WCadjBMI), waist to hip ratio adjusted for BMI (WHRadBMI), and 
height. Table 3.1 details the 18 traits, and the source published GWAS used to 
construct the GRSA models for these traits. 
To estimate GRSAs for each putative SCA risk factor, we examined 
genome-wide SNPs associated with the risk trait following stringent LD-pruning. 
For LD pruning, the ‘clump’ function implemented in PLINK v1.944,45 was  
applied on summary statistics from GWAS for risk factors to identify independent 
common variants (minor allele frequency >1%) associated with the respective 
traits. Briefly, the ‘clump’ function utilizes a P-value aware linkage 
disequilibrium (LD)-pruning approach that was used to identify index SNPs at the 
two alpha cutoffs, and exclude variants with R2 ≥ 0.01 within 1Mb of the index 
variant. For LD pruning, we used imputed genotype data from 9,747 European 
individuals from the ARIC study. For index variants with P-value <5x10-8, we 
used a more stringent approach of excluding all variants within a 1Mb radius to 
exclude any possibility of spurious association due to weak LD with the index 
SNP. A feature of this LD-pruning process is that by iteratively selecting the most 
significant SNP in a 2 MB window, followed by removing all SNPs with R2 ≥ 
0.01, even using the custom P-value cut-off, different traits are unlikely to contain 
a significant number of overlapping SNPs in the absence of significant pleiotropy. 
SNPs were also removed if not present in the CABS study, which contained over 
half of all the SCA cases. 
The associations of these SNPs with the risk factors and the SCA outcome 
are used to calculate an inverse-variance weighted multi-SNP GRSA as 
SCA SCA 
implemented in the R-package ‘MendelianRandomization’.46 This GRSA can be 
interpreted as an inverse-variance weighted, meta-analyzed (over SNPs) estimate 
of the causal log odds ratio for SCA associated with a one SD higher value of the 
risk factor from a Mendelian randomization analysis.47 It is computationally 
equivalent to the slope estimate from a zero-intercept linear regression with log 
odds ratio for the association of an additional variant allele in SNPs with SCA 
(βSCA) as the dependent variable and the mean difference associated with one 
additional variant allele in SNPs on the risk factor trait (βtrait) as the independent 
variable, weighted by the standard error of the β squared (SE 2) (Figure 3.1). 
We evaluated the use of other MR methods, including MR-Egger, simple median, 
and median-weighted. However, we found while these produced similar GRSA 
estimates as the inverse-weighted (IVW) method, these other methods had lower 
power (Table 3.2). We therefore only report the results from the IVW method. 
We also used the intercept test from the MR-Egger method to evaluate the 
presence of pleiotropy in our analyses (Table 3.2). 
The validity of this analysis requires that SNPs included can only affect 
the outcome through their effects on the risk factor (i.e. no horizontal pleiotropy). 
If there is no pleiotropy, the SNPs contributing the GRSA estimate should all 
estimate the same magnitude causal association between risk factor and SCA. We 
use the HEIDI-outlier method from the ‘gsmr’ R package to detect and remove 
potentially pleiotropic SNPs.48 Note that we report GRSA estimates from analyses 
only including SNPs that meet a stringent genome-wide significant (GWS) P- 
value cut-off (P<5x10-8), GRSA  GWS , as SNPs at this significance level likely are 
true positives and reliable instruments. However, the power for Mendelian 
randomization is dependent on the variance explained by the SNPs included in the 
GRSA, and for complex traits, the majority of the true signals may lie in SNPs 
that do not meet genome-wide significance. Therefore, we identified a somewhat 
arbitrary P-value cut-off based on visual inspection of the variance explained  
plots that largely maximizes variance explained while minimizing the number of 
SNPs (Figure 3.2). We found that all the traits fell between 0.2-0.4 P-value 
cutoff, but the results within a trait were robust to cutoffs chosen between 0.2 and 
0.4. We use a GRSA constructed with this custom P-value cut-off (GRSAmax) to 
assess only the significance of the GRSA (Pmax), as this model has the greatest 
power to assess the significance of an association. Pmax is determined by 
permutation due to inflated test statistics (Figure 3.3). At less stringent P-values, 
false-positive SNPs may be included resulting in a bias of the estimate toward the 
confounded association level. Therefore, we do not use the GRSAmax to determine 
the magnitude of the GRSA association, only its direction and significance. We 
performed two analyses, one using GRSAGWS to evaluate significance and effect 
size, and secondarily using the GRSAmax to evaluate potential associations and 
directions of effect at maximal power (Pmax). We performed multiple-testing 
adjustment on all resulting P-values (PGWS and Pmax) using a false discovery rate 
(FDR) cutoff of FDR<0.05. 
We similarly computed risk factor GRSAs on the outcome of CAD. We 
use a 1-degree of freedom Wald test to test for difference in GRSAGWS magnitudes 
between SCA and CAD. We also performed sex-specific SCA GWAS analyses to 
GW
 
construct trait GRSAs separately by sex. GRSAs were constructed from the same 
set of LD-pruned SNPs used for overall GRSAGWS analyses. P-values for 





3.3.1 CAD and CAD risk factors 
 
Prevalent CAD is an important SCA risk factor with ~80% of male SCA 
 
survivors having underlying CAD49. From GRSA  GW
S 
analysis we show that the 
 
difference in CAD status is causally associated with SCA (odds ratio in SCA risk 
 
per log odds difference in CAD, 1.36; 95% CI, 1.19-1.55; P =9.29x10-5) 
 
(Figure 3.4 and Table 3.3). While traditional CAD risk factors (blood pressure, 
lipids and diabetes) were not significantly associated with SCA at the more 
restrictive GRSAGWS threshold, using GRSAmax to maximize power, several 
additional associations were detected, including type 2 diabetes (Pmax<0.001), 
 
LDL (Pmax=0.005), total cholesterol (Pmax<0.001), triglycerides (Pmax<0.001), 
diastolic blood pressure (Pmax=0.0170), and systolic blood pressure (Pmax=0.0230) 
(Table 3.4). In the GRSAmax analysis, variants associated with higher diabetes 
risk, higher cholesterol and triglyceride levels, and higher systolic and diastolic 
blood pressure were all associated with higher SCA risk. 
 
3.3.2 Cardiac electrophysiologic factors 
 
To explore the influence of cardiac electrophysiology on SCA, we 
examined genetics of electrophysiologic traits associated with SCA: (1) atrial 
fibrillation, (2) QT interval (ventricular repolarization), (3) QRS interval 
50 
(ventricular conduction), and (4) heart rate. In the GRSAGWS analysis, we show 
that longer QT interval, a risk factor for SCA in the general population, is 
significantly associated with SCA (odds ratio in SCA risk per SD increase in QT, 
 
1.44; 95% CI, 1.13-1.83; PGWS=0.018) (Figure 3.4 and Table 3.3). Using 
 
GRSAmax, in addition to QT, we also identified a significant association of AF 
with SCA (Pmax<0.001 for both QT and AF) (Table 3.4). Variants associated with 
longer QT interval and higher AF risk were associated with higher SCA risk. By 
contrast, no significant association was seen with QRS or heart rate, even at the 
more permissive and statistically powerful GRSAmax. 
3.3.3 Anthropometric Measures 
 
The BMI GRSAGWS was significantly associated with SCA (odds ratio for 
SCA risk per SD higher BMI, 1.63; 95% CI, 1.23-2.15; PGWS=0.005) (Figure 3.4 
and Table 3.3). Using GRSAmax, we found a significant negative association 
between height and SCA (Pmax<0.001) (Table 3.4). Variants associated with 
greater height are associated with lower CAD risk51, and we correspondingly 
observed a negative GRSA between SCA and height. No significant association 
was seen with GRSAs composed of variants associated with measures of 
central/abdominal adiposity, such as waist-to-hip ratio or waist circumference. 
3.3.4 Contrasting SCA and CAD GRSAs 
 
Given the strong association of CAD with SCA, we compared the 
magnitudes of risk factor GRSAGWS on the outcomes of SCA (Figure 3.4) and 
CAD (Figure 3.5) to identify traits where risk factors may be more strongly 
 
causally associated with SCA than CAD. While the GRSAGWS for traditional CAD 
risk factors (blood pressure and lipid traits) are larger for CAD risk than SCA 
risk, we find that GRSAGWS for electrophysiologic traits of QT interval (0.34 for 
SCA vs. 0.096 for CAD, P for difference = 0.06) and AF (0.097 for SCA vs. - 
0.029 for CAD, P for difference=0.017), there was a suggestion of a larger 
association with SCA than CAD risk (Figure 3.6 and Table 3.3). 
3.3.5 Sex differences 
 
Sex differences in SCA incidence, underlying SCA pathophysiology, and 
prevalence of certain risk factors have been well documented52, yet little is known 
about whether the effect of risk factors on SCA differs by sex. Among GRSAsGWS 
where a main effect association was identified, we found a nominally significant 
 
difference in association between women and men for diabetes (0.240 for women 
vs. 0.021 for men, P for difference = 0.05) and HDL (-0.417 for women vs. 0.026 
for men, P for difference = 0.04) (Table 3.5). 
3.4 Discussion 
 
This study demonstrates that while SCA is a complex disease with 
multiple risk factors, a comprehensive genetic approach can shed light on causal 
versus correlational associations. Using Mendelian randomization with the 
European SCA GWAS (3,939 cases and 25,989 controls), we establish that 
differences in CAD, BMI, and QT interval are causally associated with SCA. 
Secondary analyses further implicate type 2 diabetes, additional traditional CAD 
risk factors such as lipids and blood pressure, as well as height and atrial 
fibrillation. Of particular interest, the GRSA estimates of phenotypes associated 
with electrical instability (AF and QT) are causally associated with SCA risk, 
more so than they are causally associated with CAD. This confirms our 
understanding of the pathophysiology of SCA─SCA is not simply fatal CAD, but 
rather, electrical instability also plays a prominent role in influencing SCA risk. 
Intriguingly, not all electrophysiologic phenotypes observationally linked 
to SCA are causally associated with SCA in our analyses. QRS interval and heart 
rate, two traits observationally associated with SCA53,54, failed to show significant 
evidence of a shared genetic basis with SCA. This lack of association may be due 
to inadequate power to identify more modest correlations. Alternatively, it may be 
that the associations from observational studies are confounded by other factors, 
and not causative (Figure 3.1B-C). For instance, underlying CAD can lead to 
both longer QRS interval and increased SCA risk; thus, while observational 
studies show an association between SCA and both traits (CAD and QRS 
interval), the association between SCA and QRS interval may not be causal. 
Similarly, the observational association of higher heart rate with SCA risk may be 
confounded by higher adrenergic state due to underlying heart disease and not 
itself be causal. Thus, the GRSA approach to examining observational risk factors 
assists in differentiating causative factors from confounded associations. 
CAD is the most common underlying pathologic substrate for SCA. It is 
reassuring, therefore, that we find significant estimated causal associations with 
SCA risk using GRSA models constructed from CAD and traditional CAD risk 
factors, including blood pressure, diabetes and cholesterol traits. 
Anthropometric measures appear to be causally associated with SCA. 
Shorter stature is associated with increased SCA risk in observational studies; our 
findings support the conclusion that this observational association is causal. 
Observational data on BMI and SCA risk have been conflicting, perhaps due to 
confounding from smoking status and frailty. Previously55, we have shown that 
increased BMI is associated with increased SCA risk in non-smokers, but not 
smokers. In this study, we find that differences in BMI, but not central/abdominal 
obesity, were causally associated with SCA risk. This finding is especially 
interesting in the context of recent data that imply different biological process 
underlying BMI and central obesity.56,57 
Finally, of the traits associated with SCA, we found that GRSAs for 
diabetes and HDL were nominally significantly different between men and 
women. While diabetes is a SCA risk factor among both sexes, previous 
observational studies have consistently suggested a stronger, albeit not 
statistically different, association among women than men58,59. These findings 
may reflect different underlying SCA pathophysiology between men and women. 
While these differences may be due to chance as they do not remain significant 
after multiple test correction, it is also likely that our study is underpowered to 
detect these differences. 
Several limitations deserve consideration. First, as somewhat addressed 
above, without detailed autopsy information, rhythm monitoring, and information 
on circumstances surrounding the cardiac arrest, the underlying etiology and 
mechanism of death may be heterogeneous and genetic associations are likely to 
be diluted. Nonetheless, clinical and autopsy studies have demonstrated a 
predominant, common pathophysiology of SCA in Western populations: VF in 
1
the setting of CAD. Hence, it is reassuring that our genetic studies suggest an 
important role for both CAD and electrical instability in SCA. Second, the 
validity of the GRSA method as a Mendelian randomization instrument rests on 
the assumption that the variant causes differences in the outcome only by its 
effects on the risk factor of interest, and not directly or by influencing other risk 
factors. Although we did not explicitly exclude SNPs associated with multiple 
risk factors (genetic pleiotropy), we did utilize a goodness-of-fit approach to 
exclude putative “pleiotropic” effects from all GRSAs. Furthermore, we 
performed a sensitivity analysis using the MR-Egger method, which tests for the 
presence of pleiotropy. Only HDL was found to be significantly influenced by 
pleiotropy (P=0.02). Lastly, while genetic pleiotropy can bias our conclusions, 
important influence is less likely when using multiple SNPs aggregated in a 
genetic risk score.60 
In conclusion, we have provided evidence for causal associations between 
 
some, but not all, observational risk factors for SCA. We show that differences in 
CAD status, BMI, and QT interval are causally associated with SCA risk. 
However, as evident in the second Mendelian randomization analysis, phenotypic 
heterogeneity is likely causing the lack of significantly causally associated risk 
factors. Further work into generating a more homogeneous phenotype is 
necessary to further explore causal SCA risk factors. 
3.5 Figures 
 




The plot (A) illustrates the process by which the QT-SCA GRSA is calculated 
using SNPs associated with QT at P<5x10-8. The points represent the effect of 
each SNP on QT (in units of standard deviation of QT) on the x-axis, and the log 
odds effect on SCA risk (corresponding 95% confidence intervals in grey) on the 
y-axis. The estimate of the genetic risk score association is the slope of the zero- 
intercept weighted regression line (solid red line). For the GRSA used in our 
analyses, the model contains a genome-wide LD-pruned SNP set (details in 
Methods). The top directed acyclic graph (B) represents a scenario in which the 
trait of interest has a causal effect on the outcome. If the GRSA, comprised of 
trait-associated variants (e.g., QT), has a significant effect on the outcome (e.g., 
SCA), it supports a causal role for the trait on the outcome. The bottom directed 
acyl graph (C) presents the case where an association is observed between the 
trait and outcome, but the GRSA comprised of trait-associated variants is not 
significantly associated with the outcome, suggesting that the observational 
association is likely being mediated by a confounding variable and the trait does 
not have a causal impact on the outcome. 



























































































































































Each data point represents a different group of SNPs set by an increasing P-value 
threshold (x-axis) and the percent of variance of a trait explained by those SNPs 
(y-axis). These plots are used to determine the fewest number of SNPs required to 
maximize the variance explained, as indicated by the dotted gray line, and are 
reported in Table 3.4 for each trait. (A) CAD = coronary artery disease; (B) T2D 
= type 2 diabetes; (C) AF = atrial fibrillation; (D) BMI = body mass index; (E) 
WCadjBMI = waist circumference adjusted for BMI; (F) WHRadjBMI = waist to 
hip ratio adjusted for BMI; (G) DBP = diastolic blood pressure; (H) SBP = 
systolic blood pressure; (I) FGadjBMI = fasting glucose adjusted for BMI; (J) 
FIadjBMI = fasting insulin adjusted for BMI; (K) HR = heart rate; (L) QRS = 
QRS interval; (M) QT = QT interval; (N) HDL = high-density lipoproteins; (O) 
LDL = low-density lipoproteins; (P) TG = triglycerides; (Q) TCH = total 
cholesterol; (R) Height. 





























1000 dummy GWAS datasets were created using genotypes of 9,533 European 
participants from the ARIC cohort and 1000 randomly generated quantitative 
phenotypes (mean=0, sd=1). These datasets were subsequently used to compute a 
GRSA estimate for SCA with (A) P<5x10-8 and (B) P<0.3. Each panel plots the - 
log10(P-value) of GRSs constructed from these datasets at the different alphas, 
and represents the null distribution of GRSA P-values. These null distributions 
were used to determine the permutated P-value in Table 3.4. 
Figure 3.4: Genetic Risk Scores Association (GRSA) Estimates for SCA using 




These data points represent the exponentiated GRSA estimates of 18 traits on 
sudden cardiac arrest (SCA) and corresponding 95% confidence interval values 
using the previously published SCA GWAS with 3,989 cases and 25,989 controls. 
The GRSA estimates in the top panel for the binary traits are in log odds units. 
Values in bottom panel are in SD units of the quantitative traits. GRSA estimates 
and significance are derived from SNPs associated with each trait at P<5x10-8. 
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The significance of the GRSAGWS estimates (FDR adjusted PGWS) are represented 
as “*” for P<0.05, “**” for P<0.01, and “***” for P<0.001. The significance of 
the secondary analysis using GRSAmax estimates (FDR adjusted permuted Pmax) 
are represented as “+” for P<0.05, “++” for P<0.01 and “+++” for P<0.001. For 
details on values of GRSA estimates and P-values, see Table 3.3. CAD = 
coronary artery disease; T2D = type 2 diabetes; AF = atrial fibrillation; BMI = 
body mass index; WCadjBMI = waist circumference adjusted for BMI; 
WHRadBMI = waist to hip ratio adjusted for BMI; DBP = diastolic blood 
pressure; SBP = systolic blood pressure; FGadjBMI = fasting glucose adjusted for 
BMI; FIadjBMI = fasting insulin adjusted for BMI; HR = heart rate; QRS = QRS 
interval; QT = QT interval; HDL = high-density lipoproteins; LDL = low-density 
lipoproteins; TCH = total cholesterol; TG = triglycerides. 




These data points represent the exponentiated GRSA estimates of 17 traits on 
coronary artery disease (CAD) and corresponding 95% confidence interval 
values. The GRSA estimates in the top panel for the binary traits are in log odds 
units. Values in bottom panel are in SD units of the quantitative traits. GRSA 
estimates and significance are derived from SNPs at P<5x10-8. The significance 
of the GRSAGWS estimates (PGWS) are represented as “*” for P<0.05, “**” for 
P<0.01, and “***” for P<0.001. The significance of the secondary analysis using 
GRSAmax estimates (permuted Pmax) are represented as “+” for P<0.05, “++” for 
P<0.01 and “+++” for P<0.001. For details on values of GRSA estimates and P- 
values, see Table 3.3. T2D = type 2 diabetes; AF = atrial fibrillation; BMI = body 
mass index; WCadjBMI = waist circumference adjusted for BMI; WHRadBMI = 
waist to hip ratio adjusted for BMI; DBP = diastolic blood pressure; SBP = 
systolic blood pressure; FGadjBMI = fasting glucose adjusted for BMI; FIadjBMI 
= fasting insulin adjusted for BMI; HR = heart rate; QRS = QRS interval; QT = 
QT interval; HDL = high-density lipoproteins; LDL = low-density lipoproteins; 
TCH = total cholesterol; TG = triglycerides. 






These data represent exponentiated GRSAs of all 17 traits. GRSA estimates for 
SCA and CAD, are plotted in orange and teal respectively. Bars around the 
estimates represent the 95% confidence interval. The GRSA estimates in the top 
panel for the binary traits are in log odds units. Values in bottom panel are in SD 
units of the quantitative traits. The level of significance for 1 degree of freedom 
Wald test of difference in GRSAGWS estimates between SCA and CAD is 
represented “*” for P<0.05, “**” for P<0.01, and “***” for P<0.001. T2D = type 
2 diabetes; AF = atrial fibrillation; BMI = body mass index; WCadjBMI = waist 
circumference adjusted for BMI; WHRadBMI = waist to hip ratio adjusted for 
BMI; DBP = diastolic blood pressure; SBP = systolic blood pressure; FGadjBMI 
= fasting glucose adjusted for BMI; FIadjBMI = fasting insulin adjusted for BMI; 
HR = heart rate; QRS = QRS interval; QT = QT interval; HDL = high-density 




Table 3.1 Study Details 
Trait Abbreviation Consortium Title Total Sample Size 
 





Large-scale association analysis identifies 
new risk loci for coronary artery disease 












Large-scale association analysis provides 
insights into the genetic architecture and 
pathophysiology of type 2 diabetes (Morris 













Large-scale analyses of common and rare 
variants identify 12 new loci associated 











Genetic studies of body mass index yield 










Defining the role of common variation in 
the genomic and biological architecture of 










New genetic loci link adipose and insulin 











New genetic loci link adipose and insulin 



















Genetic variants in novel pathways 
influence blood pressure and 
cardiovascular disease risk (Ehret et al., 
2011) & The genetics of blood pressure 
regulation and its target organs from 
association studies in 342,415 individuals 















Title Total Sample Size 
 
 







Genetic variants in novel pathways influence 
blood pressure and cardiovascular disease 
risk (Ehret et al., 2011) & The genetics of 
blood pressure regulation and its target 














A genome-wide approach accounting for 
body mass index identifies genetic variants 
influencing fasting glycemic traits and insulin 













A genome-wide approach accounting for 
body mass index identifies genetic variants 
influencing fasting glycemic traits and insulin 













Identification of genomic loci associated 
with resting heart rate and shared genetic 
predictors with all-cause mortality (Eppinga 





















Genetic association study of QT interval 
highlights role for calcium signaling 
pathways in myocardial repolarization 







HDL Global Lipids Genetics Consortium 
Discovery and refinement of loci associated 






LDL Global Lipids Genetics Consortium 
Discovery and refinement of loci associated 






TCH Global Lipids Genetics Consortium 
Discovery and refinement of loci associated 






TG Global Lipids Genetics Consortium 
Discovery and refinement of loci associated 


























CAD 23 0.307 [0.175,0.440] 5.16x10-6 0.365 [0.032,0.698] 0.032 -0.007 0.71 
T2D 38 0.063 [-0.052,0.177] 0.29 0.014 [-0.265,0.293] 0.92 0.006 0.71 
AF 19 0.097 [-0.024,0.218] 0.12 0.009 [-0.229,0.247] 0.94 0.013 0.40 
BMI 72 0.488 [0.209,0.767] 6.02x10-4 0.864 [0.183,1.55] 0.013 -0.012 0.24 
Height 447 -0.100 [-0.212,0.013] 0.08 -0.06 [-0.368,0.248] 0.70 -0.001 0.79 
WCadjBMI 67 -0.358 [-0.715,-0.001] 0.05 -0.429 [01.95,1.09] 0.58 0.002 0.92 
WHRadjBMI 39 -0.404 [-0.864,0.056] 0.09 -1.92 [-4.26,0.419] 0.11 0.043 0.20 
DBP 54 0.093 [-0.121,0.307] 0.39 0.363 [-0.224,0.951] 0.23 -0.013 0.33 
SBP 54 0.208 [-0.410,0.826] 0.51 0.593 [-1.11,2.30] 0.49 -0.006 0.63 
FGadjBMI 22 0.203 [-0.051,0.456] 0.12 0.432 [-0.103,0.966] 0.11 -0.019 0.34 
FIadjBMI 9 -0.113 [-0.874,0.648] 0.77 -1.247 [-5.63,3.132] 0.58 0.036 0.61 
HR 67 -0.188 [-0.414,0.038] 0.10 -0.760 [-1.38,-0.137] 0.017 0.023 0.05 
QRS 22 -0.027 [-0.395,0.342] 0.89 -0.834 [-2.15,0.481] 0.21 0.036 0.21 
QT 60 0.365 [0.125,0.605] 0.003 0.571 [0.101,1.041] 0.017 -0.009 0.32 
HDL 89 -0.099 [-0.279,0.081] 0.28 0.230 [-0.096,0.556] 0.17 -0.017 0.019 
LDL 68 0.142 [-0.070,0.355] 0.19 0.198 [-0.190,0.586] 0.32 -0.003 0.73 
TCH 85 0.158 [-0.032,0.349] 0.10 0.021 [-0.340,0.381] 0.91 0.008 0.38 









Simple Median Estimate 
[95% CI] 
 
SimpleMedia  Median Weighted Estimate 




CAD 23 0.304 [0.100,0.507] 0.003 0.329 [0.128,0.531] 0.001 
T2D 38 0.018 [-0.139,0.175] 0.82 0.056 [-0.106,0.218] 0.50 
AF 19 0.158 [-0.035,0.351] 0.11 0.053 [-0.112,0.219] 0.53 
BMI 72 0.426 [-0.025,0.877] 0.06 0.729 [0.250,1.21] 0.003 
Height 447 -0.165 [-0.340,0.011] 0.07 -0.084 [-0.264,0.095] 0.36 
WCadjBMI 67 -0.527 [-0.985,-0.069] 0.024 -0.519 [-0.977,-0.061] 0.026 
WHRadjBMI 39 -0.45 [-1.02,0.122] 0.12 -0.547 [-1.12,0.022] 0.06 
DBP 54 0.090 [-0.228,0.407] 0.58 0.070 [-0.239,0.380] 0.66 
SBP 54 0.218 [-0.694,1.13] 0.64 0.180 [-0.707,1.07] 0.69 
FGadjBMI 22 0.160 [-0.236,0.556] 0.43 0.472 [0.147,0.798] 0.004 
FIadjBMI 9 -0.225 [-1.27,0.824] 0.67 -0.271 [-1.27,0.729] 0.60 
HR 67 -0.184 [-0.531,0.162] 0.30 -0.260 [-0.601,0.082] 0.14 
QRS 22 -0.061 [-0.535,0.413] 0.80 -0.074 [-0.543,0.395] 0.76 
QT 60 0.428 [0.027,0.829] 0.037 0.470 [0.106,0.835] 0.011 
HDL 89 -0.053 [-0.347,0.240] 0.72 0.029 [-0.254,0.312] 0.84 
LDL 68 0.088 [-0.225,0.400] 0.58 0.196 [-0.100,0.491] 0.19 
TCH 85 0.100 [-0.183,0.383] 0.49 0.025 [-0.230,0.280] 0.85 
TG 58 0.066 [-0.308,0.439] 0.73 -0.129 [-0.449,0.190] 0.43 
 
Table 3.3A: SCA GRSA with 18 traits using SNPs with P<5x10-8 
 
TRAIT Number of SNPs GRSA estimate [95% CI] P-value for GRSA FDR adjusted P-value 
CAD 23 0.307 [0.175,0.440] 5.16x10-6 9.29x10-5 
T2D 38 0.063 [-0.052,0.177] 0.29 0.38 
AF 19 0.097 [-0.024,0.218] 0.12 0.24 
BMI 72 0.488 [0.209,0.767] 6.02x10-4 5.42x10-3 
HEIGHT 449 -0.100 [-0.212,0.013] 0.08 0.29 
WCADJBMI 65 -0.358 [-0.715,-0.001] 0.05 0.23 
WHRADJBM 39 -0.404 [-0.864,0.056] 0.09 0.27 
DBP 54 0.093 [-0.121,0.307] 0.39 0.47 
SBP 54 0.208 [-0.410,0.826] 0.51 0.58 
FGADJBMI 22 0.203 [-0.051,0.456] 0.12 0.22 
FIADJBMI 9 -0.113 [-0.874,0.648] 0.77 0.82 
HR 67 -0.188 [-0.414,0.038] 0.10 0.26 
QRS 22 -0.027 [-0.395,0.342] 0.89 0.89 
QT 60 0.365 [0.125,0.605] 0.003 0.018 
HDL 90 -0.099 [-0.279,0.081] 0.28 0.39 
LDL 66 0.142 [-0.070,0.355] 0.19 0.32 
TCH 84 0.158 [-0.032,0.349] 0.10 0.23 
TG 55 0.150 [-0.075,0.376] 0.19 0.29 
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Number of SNPs 
 
 
GRSA estimate [95% CI] 
 
 
P-value for GRSA 
 
 




SCA and CAD 
T2D 38 0.090 [0.049, 0.131] 1.66x10-5 3.53x10-5 0.817 
AF 19 -0.029 [-0.086, 0.028] 0.317 0.337 0.017 
BMI 71 0.327 [0.201, 0.452] 3.30x10-7 8.01x10-7 0.303 
HEIGHT 455 -0.156 [-0.207, -0.106] 1.07x10-9 3.03x10-9 0.269 
WCADJBMI 67 0.022 [-0.116, 0.160] 1.66x10-5 3.14x10-5 0.066 
WHRADJBM 40 0.365 [0.195, 0.535] 2.51x10-5 3.88x10-5 0.005 
DBP 54 0.489 [0.396, 0.583] 1.41x10-24 5.99x10-24 0.023 
SBP 54 1.37 [1.10, 1.64] 2.62x10-23 8.90x10-23 2.00x10-4 
FGADJBMI 22 0.0547 [-0.040, 0.150] 0.258 0.313 0.277 
FIADJBMI 9 0.223 [-0.121, 0.566] 0.204 0.267 0.426 
HR 63 -0.026 [-0.128, 0.075] 0.610 0.610 0.208 
QRS 21 -0.087 [-0.237, 0.064] 0.258 0.292 0.776 
QT 61 0.096 [-0.001, 0.201] 0.073 0.103 0.063 
HDL 82 -0.166 [-0.243, -0.089] 2.16x10-5 3.67x10-5 0.533 
LDL 66 0.493 [0.419, 0.566] 1.41x10-39 1.20x10-38 0.001 
TCH 80 0.515 [0.444, 0.586] 9.65x10-46 1.64x10-44 0.004 
TG 54 0.538 [0.440, 0.637] 6.31x10-27 3.58x10-26 0.003 
 






























CAD 0.4 32,252 0.050 [0.039, 0.061] 4.81x10-19 <0.001 <0.001 
T2D 0.3 29,276 0.041 [0.031, 0.050] 1.72x10-17 <0.001 <0.001 
AF 0.3 31,196 0.045 [0.032, 0.058] 2.73x10-11 <0.001 <0.001 
BMI 0.4 29,478 0.095 [0.044, 0.146] 2.57x10-4 0.006 0.012 
HEIGHT 0.2 19,651 -0.162 [-0.215, -0.110] 1.29x10-9 <0.001 <0.001 
WCADJBMI 0.3 27,081 -0.044 [-0.089, -0.001] 0.047 0.13 0.18 
WHRADJBMI 0.3 28,111 -0.004 [-0.047, 0.039] 0.85 0.89 0.89 
DBP 0.3 27,871 0.051 [0.020, 0.081) 0.001 0.017 0.031 
SBP 0.3 27,820 0.052 [0.018, 0.085] 0.002 0.023 0.038 
FGADJBMI 0.2 24,415 0.003 [-0.023, 0.029] 0.82 0.88 0.93 
FIADJBMI 0.4 34,051 -0.014 [-0.051, 0.023] 0.45 0.57 0.69 
HR 0.2 24,471 -0.013 [-0.056, 0.030] 0.56 0.66 0.74 
QRS 0.3 29,636 -0.030 [-0.067, 0.007] 0.11 0.24 0.30 
QT 0.3 30,129 0.108 [0.056, 0.159] 4.06x10-5 0.002 0.005 
HDL 0.4 29,737 -0.050 [-0.088, -0.011] 0.011 0.05 0.08 
LDL 0.4 30,177 0.066 [0.032, 0.101] 1.86x10-4 0.005 0.011 
TCH 0.4 30,036 0.097 [0.062, 0.133] 5.90x10-8 <0.001 <0.001 
TG 0.4 30,505 0.095 [0.057, 0.134] 9.89x10-7 <0.001 <0.001 
 
























T2D 0.3 28,184 0.051 [0.047, 0.056] 2.30x10-109 <0.001 <0.001 
AF 0.3 29,300 0.033 [0.026, 0.039] 2.46x10-24 <0.001 <0.001 
BMI 0.4 27,872 0.089 [0.065, 0.113] 3.93x10-13 <0.001 <0.001 
HEIGHT 0.2 18,695 -0.117 [-0.142, -0.092] 1.65x10-20 <0.001 <0.001 
WCADJBMI 0.3 25,780 -0.003 [-0.023, 0.018] 0.80 0.85 0.85 
WHRADJBMI 0.3 26,709 0.062 [0.042, 0.082] 2.33x10-9 <0.001 <0.001 
DBP 0.3 26,029 0.054 [0.038, 0.067] 1.55x10-11 <0.001 <0.001 
SBP 0.3 25,859 0.078 [0.061, 0.095] 2.43x10-19 <0.001 <0.001 
FGADJBMI 0.2 22,814 0.010 [-0.003, 0.023] 0.14 0.26 0.29 
FIADJBMI 0.4 31,601 0.043 [0.024, 0.063] 1.47x10-5 <0.001 <0.001 
HR 0.2 22,991 0.014 [-0.006, 0.034] 0.17 0.29 0.31 
QRS 0.3 27,648 0.018 [0.001, 0.049] 0.046 0.13 0.15 
QT 0.3 27,905 0.044 [0.012, 0.068] 6.95x10-4 0.011 0.014 
HDL 0.4 28,799 -0.062 [-0.075, -0.049] 1.24x10-11 <0.001 <0.001 
LDL 0.4 29,412 0.078 [0.062, 0.094] 3.83x10-21 <0.001 <0.001 
TCH 0.4 29,101 0.050 [0.034, 0.067] 4.07x10-9 <0.001 <0.001 
TG 0.4 29,650 0.075 [0.057, 0.093] 2.27x10-16 <0.001 <0.001 
 
 
Table 3.5A: Sex-stratified SCA GRSA for 18 traits using SNPs with P<5x10-8 -Men 
 
Trait Number of SNPs 
 
GRSA estimate (95% CI) 
 
P-value for GRSA 
CAD 23 0.329 [0.168, 0.490] 5.98x10-5 
T2D 39 0.021 [-0.100, 0.141] 0.74 
AF 19 0.063 [-0.083, 0.209] 0.40 
BMI 72 0.603 [0.269, 0.937] 3.97x10-4 
HEIGHT 462 -0.023 [-0.157, 0.110] 0.73 
WCADJBMI 68 -0.268 [-0.641, 0.105] 0.16 
WHRADJBMI 40 -0.494 [-0.963, -0.026] 0.039 
DBP 47 0.156 [-0.323, 0.646] 0.52 
SBP 45 0.149 [-0.362, 0.660] 0.57 
FGADJBMI 22 0.072 [-0.177, 0.321] 0.57 
FIADJBMI 9 -0.687 [-1.61, 0.232] 0.14 
HR 68 -0.205 [-0.477, 0.066] 0.14 
QRS 22 0.063 [-0.351, 0.477] 0.77 
QT 64 0.245 [-0.037, 0.528] 0.09 
HDL 90 0.026 [-0.181, 0.232] 0.81 
LDL 70 0.253 [0.051, 0.455] 0.014 
TCH 86 0.189 [-0.001, 0.380] 0.05 




Number of  




difference in GRSA 
by sex 
CAD 23 0.267 [0.014, 0.519] 0.039 0.64 
T2D 39 0.240 [0.053, 0.427] 0.012 0.048 
AF 19 0.107 [-0.124, 0.338] 0.37 0.65 
BMI 72 0.469 [-0.060, 0.997] 0.08 0.68 
HEIGHT 464 -0.220 [-0.429, -0.011] 0.039 0.15 
WCADJBMI 68 -0.492 [-1.08, 0.093] 0.09 0.54 
WHRADJBMI 40 -0.005 [-0.740, 0.730] 0.99 0.3 
DBP 47 0.334 [-0.413, 1.08] 0.38 0.71 
SBP 45 0.268 [-0.531, 1.07] 0.51 0.81 
FGADJBMI 22 0.546 [0.155, 0.937] 0.006 0.044 
FIADJBMI 9 0.778 [-0.693, 2.25] 0.30 0.11 
HR 68 -0.235 [-0.663, 0.194] 0.28 0.11 
QRS 22 -0.215 [-0.857, 0.427] 0.51 0.37 
QT 63 0.615 [0.167, 1.06] 0.007 0.32 
HDL 90 -0.417 [-0.743, -0.091] 0.012 0.043 
LDL 71 -0.039 [-0.343, 0.264] 0.80 0.15 
TCH 85 0.034 [-0.263, 0.331] 0.82 0.23 
TG 60 0.283 [-0.094, 0.660] 0.14 0.47 
 
 
Table 3.5B: Sex-stratified SCA GRSA for 18 traits using SNPs with P<5x10-8 -Women 
Chapter 4: The effect of sex and underlying disease on the genetic 
association of QT interval and sudden cardiac arrest 
4.1 Introduction 
 
SCA is often the first manifestation of heart disease, particularly for 
women; several studies have found that women are less likely than men to have a 
prior history of known cardiac disease.15,61 It has been hypothesized that SCA is a 
much more heterogeneous condition in women, potentially due to the different 
underlying diseases, leading to differences in the associated risk factors. 
Prolonged QT interval, a measure of ventricular repolarization, has been 
previously established as a risk factor for SCA,62,63 and recent studies using 
Mendelian randomization have demonstrated that this risk factor is causal.38 
Women, on average, exhibit longer QT intervals than men in the general 
population once puberty is reached.64,65 In addition, a previous study found that 
the increase in risk for overall cardiac death associated with longer QT interval 
was more pronounced in women.66 Women also have higher risk of arrhythmic 
events than men in the setting of inherited or acquired (drug-induced) QT 
prolongation.67 Based on the sex differences in QT interval in the general 
population and its association with overall cardiac mortality, we hypothesize that 
the risk of SCA associated with longer QT interval could differ by sex. Likewise, 
we also hypothesize that QT interval could differentially affect SCA risk 
depending on the underlying pathology (e.g. ischemic vs. non-ischemic disease). 
Previous studies have shown that ~34% of QT interval variation is 
heritable68,69. In addition, recent research indicates that ~21% of variation can be 
explained by common autosomal SNPs found genome-wide, including SNPs in 
genes such as KCNQ1, KCNH2, SCN5A and NOS1AP.70 The top SNP from the 
most recent QT interval genome-wide association study (GWAS) was the 
NOS1AP locus SNP rs12143842, which increased QT interval by 3.50 ms per T- 
allele (p-value=1x10-213)33 and accounts for ~1% of the variation in QT interval.71 
This SNP has been previously associated with increased SCA risk72,73, and has 
 
also been found to have stronger effect on QT interval in women than men.71 
 
In this study we examined a large Finnish study of post-mortem autopsy- 
confirmed SCA subjects to study the genetic association between QT interval and 
SCA risk. More specifically, we compared the association of the NOS1AP locus 
variant rs12143842 with SCA risk between subjects with underlying ischemic vs. 
non-ischemic disease. We also performed sex-stratified analyses within these 
groups to investigate any sex-specific association of the NOS1AP locus SNP with 
SCA risk. Finally, we performed Mendelian randomization to test for differences 
in the causal association between a previously identified causal risk factor, longer 






Samples from the Fingesture and NFBC1966 studies, as described in 
Chapter 3, were genotyped for rs12143842 using five different platforms: 
Illumina Infinium Global Screening Array (GSA); Affymetrix Genome-wide 
Human SNP Array 6.0; Agena Biosciences MassARRAY; Applied Biosystems 
Taqman real-time PCR; and Illumina TruSeq sequencing. All genotyping and 
sequencing were performed according to the manufacturer’s instructions. Quality 
control was performed separately on each dataset before merging. Dataset and QC 
information is summarized in Table 4.1. Overlapping samples between platforms 
were used to evaluate the accuracy of the genotyping (reported in Supplementary 
Table 1). After exclusions, the study population included 2,282 SCA victims and 
3,561 Finnish controls. 
4.2.2 Statistical Analysis 
 
P-values for differences in the Fingesture study characteristics were 
calculated using a two sample t-test for continuous variables and Pearson chi- 
square test for categorical variables. The genotypes for rs12143842 for all  
samples were merged and logistic regression was performed using R (version 
3.3.3), with sex as the only covariate. The SCD cases were stratified by sex and 
underlying disease (ischemic, non-ischemic and other disease) to examine the 
SNP effects in each group. Differences between sexes were determined by 
incorporating an interaction term into the regression model. P-values for 
differences in effect sizes between the underlying disease groups were obtained 
from a 1-degree of freedom Wald test. Multi-dimensional scaling (MDS) using 
PLINKv1.9 was used for samples run on the GSA microarray (1,168 cases/761 
controls) to assess potential population substructure between the Fingesture and 
NFBC1966 studies. MDS is a method that reduces the high number of dimensions 
(i.e. the number of SNPs) to a smaller number of dimensions based on similarities 
in the data and orders these MDS dimensions (called components) based on the 
amount of variation explained in the data.74 Most often, population substructure 
accounts for the most variation within the data and is captured in the first several 
MDS components. 
4.2.3 Mendelian Randomization 
 
While association tests establish observational relationships between a  
trait (i.e. QT interval) and an outcome (i.e. SCD), they cannot establish causality. 
Confounding variables, variables affecting both the trait and the outcome, can 
result in false positive associations. Mendelian randomization circumvents these 
potential confounders to establish causality by exploiting certain characteristics of 
SNPs: that they are (1) assigned at conception and (2) randomly distributed in the 
large population.60,75 Mendelian randomization has other assumptions that must be 
met as well, including the absence of pleiotropy.76 This assumption is often hard 
to fully meet, leading to potential bias of the results. However, recent methods 
have been developed to remove potentially pleiotropic SNPs in order to meet this 
assumption. 
Mendelian randomization uses genetic variants as instrumental variables  
to test for causal relationships between a trait and an outcome. We used a multi- 
SNP genetic risk score association (GRSA) model to test for causality between 
QT interval and SCD in our stratified datasets. The SNPs used in the model are 
known to be associated with the trait of interest. In this study, we used genome- 
wide significant SNPs from the most recent QT interval GWAS.33 The SNPs were 
pruned for linkage disequilibrium (LD) using the ‘clump’ method in PLINKv1.9, 
which removes any SNP within a 1Mb window of the SNP with the lowest P- 
46 
value. This step is performed in order to remove any correlated SNPs and reduce 
any potential bias. The GRSA model uses 57 LD-pruned SNPs to compare the 
association of these SNPs with the trait of interest (βtrait) to the association of the 
 
SNPs with SCD (βoutcome) using the R package 'MendelianRandomization’. Zero- 
 
intercept inverse-weighted (IVW) linear regression is used to calculate the GRSA 
estimate, which is the slope of the resultant regression line, and estimates the 
difference in log odds of SCD risk per SD increase in QT interval. We used the 
HEIDI-outlier method from the ‘gsmr’ R package to detect and remove 
potentially pleiotropic SNPs.48 P-values for difference in GRSA estimates were 
obtained from a 1-degree of freedom Wald test. 
Genome-wide SNP data is required for Mendelian randomization analyses 
and therefore only the Fingesture and NFBC1966 samples genotyped using the 
Infinium Global Screening Array (GSA) and imputed to the NHLBI Trans-Omics 
for Precision Medicine (TOPMed) imputation panel using the University of 
Michigan imputation server77 were used in this analysis (1,168 SCD victims and 
761 Finnish controls). Logistic regression for single SNP association tests were 
run using FASTv2.4.37 We performed several stratified analyses, including by sex 
and underlying disease (ischemic and non-ischemic disease). There were a small 
number of SCD cases with other underlying disease genotyped on this array and 
therefore were only included in the overall analysis and sex-stratified analyses but 





4.3.1 Sample population 
 
The SCA population is comprised of a subset of the Fingesture study of 
Finnish SCA subjects with autopsy-confirmed assessment of underlying heart 
disease in whom DNA was available at the time of this study (n=2,282). Controls 
were drawn from the Northern Finland Birth Cohort of 1966 (NFBC1966) and are 
comprised of 3,561 Finnish individuals born in 1966. Characteristics of the 
Fingesture study are detailed in Table 4.2. Additional information about the 
different sample subgroups is provided in Table 4.3. To assess for potential 
population stratification, we ran multi-dimensional scaling (MDS) on a subset of 
the samples with genome-wide SNP data (1,168 cases/761 controls). We assessed 
the top 10 MDS components, which can be used to visualize potential population 
substructure, for association with SCD status to test for possible confounding of 
our SNP association results. We ran logistic regression for SCD status, including 
sex and the top 10 MDS components as covariates. Results are in Table 4.4. Plots 
for the top 10 MDS components, colored by SCA status, are found in Figure 4.1. 
MDS component 7 was associated with SCA status after multi-test correction 
(P<0.002) (Table 4.4), indicating the potential for confounding due to population 
substructure. However, combined, the top 10 components explained only 0.9% of 
the variance in SCA status, suggesting likely minimal impact. This minimal 
impact was confirmed by sensitivity analyses (described below). 
4.3.2 NOS1AP locus SNP analysis 
 
Given the previously established relationship between QT interval and 
SCA risk, and with NOS1AP locus SNPs and SCA in other cohorts63,78, we first 
sought to assess the association between SCA and the NOS1AP locus SNP 
rs12143842. When analyzing all 2,282 SCA cases and 3,561 controls, the T allele 
of rs12143842 was significantly associated with increased SCA risk with an OR 
of 1.14 for each copy of the QT lengthening allele (95% CI, 1.04-1.25; P = 
0.005). In sensitivity analyses, including the 10 top components from the MDS 
analysis in the model minimally increased the effect estimate (Table 4.5). All 
SNP association results are summarized in Figure 4.2 and Table 4.6. 
4.3.2a Ischemic vs. Non-ischemic 
 
To explore whether the association of rs12143842 differs by underlying 
disease pathology, we stratified the SCA cases into those with (1) underlying 
ischemic heart disease (n=1,478), (2) non-ischemic heart disease (n=750), and (3) 
other pathologies (myocarditis, cardiac anomaly, and normal autopsy, n=54). The 
rs12143842 T allele had the strongest association in non-ischemic SCA 
individuals with an OR of 1.23 (95% CI, 1.07-1.39; P=0.003). A weaker non- 
significant association was observed in both ischemic SCA individuals (OR 
=1.09; 95% CI, 0.98-1.21; P=0.12), and those with other underlying conditions 
(OR = 1.11; 95% CI, 0.71-1.73; P=0.64). 
4.3.2b Men vs. Women 
 
Given that QT interval is a stronger SCA risk factor in men than women, 
and rs12143842 has a larger effect on QT interval in women than in men,71 we 
next investigated whether the effect of rs12143842 on SCA risk differed between 
men and women. We limited sex-stratified analyses to SCA cases with underlying 
ischemic and non-ischemic pathology and excluded those with other underlying 
conditions due to the small sample size of those with other conditions. 
Among 1,862 SCA male victims and 1,641 male controls, the rs12143842 
QT lengthening allele was marginally associated with an increased risk of SCA 
(OR of 1.11; 95% CI, 0.99-1.23; P=0.07). When stratified by underlying disease 
pathology, the association was significant among non-ischemic SCA males (579 
cases/1,641 controls) with an OR of 1.17 (95% CI, 1.00-1.37; P=0.045), while 
there was no statistically significant association in ischemic SCA males (1,245 
cases/1,641 controls) for SCA risk (OR =1.09; 95% CI, 0.96-1.23; P=0.18; P for 
difference between ischemic/non-ischemic males=0.48). 
Overall, among 420 female SCA cases and 1,920 female controls, the 
rs12143842 QT lengthening allele was associated with increased SCA risk (OR of 
1.24; 95% CI, 1.04-1.46; P=0.015). Similar to findings among men, a stronger 
association was observed in the non-ischemic SCA women (171 cases/1,920 
controls), with the rs12143842 T allele association with a 1.37-fold increased 
SCA risk (95% CI, 1.07-1.75; P=0.013) than among ischemic SCA women (233 
cases/1,920 controls) (OR = 1.11 for each copy of the variant allele; 95% CI, 
0.88-1.38; P=0.39; P for difference between ischemic/non-ischemic 
women=0.08). 
4.3.3 Mendelian Randomization of QT Interval 
 
Using Mendelian randomization approaches, we have previously 
established that QT interval is causally associated with SCA.38 To investigate 
whether these causal associations differ based on sex and underlying disease, we 
calculated genetic risk score association (GRSA) estimates using the genome- 
wide significant SNPs from the most recent QT interval GWAS.33 Inverse- 
weighted (IVW) linear regression was performed to compare the effect of the 
SNP on QT interval to the effect of the SNP on SCA risk in the sex-stratified and 
underlying disease-stratified datasets. Results are summarized in Figure 4.3 and 
Table 4.7. 
Among all SCA victims (n=1,168 cases/761 controls), a one standard 
deviation (SD) increase in QT interval was associated with a 1.42-fold increased 
risk of SCA (95% CI, 0.83-2.45; P=0.20), which translates in our sample 
population to a 1.10-fold increased risk of SCD per 10 ms increase in QT interval 
(95% CI, 0.90-1.34, P=0.20). While not statistically significant, these findings are 
consistent with our previous work (previous findings: odds ratio in cardiac arrest 
risk per SD increase in QT, 1.44; 95% CI, 1.13-1.83; P=0.018)38. Similar to our 
findings with NOS1AP locus SNP rs12143842, we found that the causal 
relationship of QT interval and SCA differs between individuals with ischemic 
heart disease and individuals with non-ischemic disease. Among non-ischemic 
SCA victims (507 cases/761 controls), there was a 1.96-fold increase in SCA risk 
per SD increase in QT (95% CI, 1.00-3.82; P=0.05). By contrast, there was no 
evidence of a causal association of QT interval with SCA among SCA cases with 
ischemic disease (611 cases/761 controls; OR= 0.88; 95% CI, 0.47-1.67; P=0.70). 
Non-ischemic female SCA cases had the strongest causal association of 
QT interval with SCA (odds ratio in SCA risk per SD increase in QT, 3.60; 95% 
CI, 1.22-10.59; P=0.02). Non-ischemic males had a large but non-significant 
causal association estimate between QT interval and SCA (odds ratio in SCA risk 
per SD increase in QT, 1.47; 95% CI, 0.64-3.39; P=0.36). Among those with 
underlying ischemic disease, there was no evidence for a causal relationship of 
QT interval with SCA for men or women (odds ratio in SCA risk per SD increase 
in QT, 0.92; 95% CI, 0.41-2.05; P=0.84 and odds ratio in SCA risk per SD 
increase in QT, 0.80; 95% CI 0.22-2.94; P=0.74, respectively). 
4.4 Discussion 
 
In the general population, women have longer QT intervals than men; 
women experience a higher rate of arrhythmias in the setting of prolonged QT 
interval; and prolonged QT interval is causally associated with SCD. We therefore 
hypothesized that women would show a greater association between genetically 
determined longer QT interval and SCD. Given the different etiologies between 
ischemic and non-ischemic cardiac disease, we further hypothesized that the 
genetic association with longer QT interval would also differ between the  
different underlying diseases. Our results, while not conclusive, support both of 
these hypotheses. We found that rs12143842, the top QT interval-associated SNP 
from previous GWAS33, was associated with SCD risk in our overall dataset. We 
observed a larger, yet not statistically significant, genetic effect on SCD risk in 
non-ischemic individuals compared to ischemic individuals. Furthermore, the 
women with SCD in the setting of non-ischemic cardiac disease had the largest 
genetic effect of rs12143842 on SCD risk. Our Mendelian randomization analyses 
had similar findings; non-ischemic individuals showed a potential causal 
association between longer QT interval and SCD, and female non-ischemic 
individuals had the strongest causal association. By contrast, both the SNP 
association and Mendelian randomization analyses did not show evidence for a 
genetic (causal) association between QT interval and SCD due to underlying 
ischemic disease in men or women. These results suggest that SCD in the setting 
of ischemic disease may not be strongly influenced by myocardial repolarization 
(QT interval), or that the effect of longer QT interval on ischemic SCD risk is 
masked by other risk factors exerting a larger effect. While the differences in sex- 
and underlying disease-stratified associations were not statistically significant, the 
directionality of our findings is nevertheless consistent with our underlying 
hypotheses; together these results provide evidence that SCD risk in non-ischemic 
individuals, particularly women with non-ischemic disease, may be influenced by 
genetically determined QT interval. 
The underlying cause(s) of the sex differences in the association between 
longer QT interval and SCD remains unknown, however, sex hormones may play 
a role. Studies have previously established that testosterone and progesterone 
shorten the QT interval, while estrogen lengthens the QT interval.79,80 While the 
underlying mechanism is unknown, our findings support the hypothesis that non- 
ischemic individuals are more susceptible to the effects of longer QT interval on 
developing SCD. Given that women already have underlying lengthened QT due 
to sex hormones, the addition of QT lengthening genetic susceptibility (i.e. the T 
allele of the NOS1AP SNP rs12143842) may result in the higher observed risk of 
SCD in women with non-ischemic disease. 
While our study provides evidence for differences in SCD risk factors 
between both underlying disease and sex, several limitations should be noted. 
First, many of our analyses did not meet traditional statistical significance cut- 
offs, though we note that the directionality of the results is entirely consistent with 
our original hypotheses. The study is underpowered to detect interactions and 
thus, additional samples are necessary to confirm our results. Our findings in the 
subgroup analyses also require additional replication. Second, there is likely 
additional phenotypic heterogeneity within the underlying disease subgroups. The 
non-ischemic group, as noted in the supplementary methods, consists of eight 
different cardiac conditions. It is possible these different conditions, while similar 
in nature, may differ in their relationship between QT interval and SCD risk. 
Additional samples are needed to further stratify the non-ischemic group to 
investigate whether a particular condition is driving the association. Third, while 
our MDS components indicated potential population substructure within a subset 
of samples, when we included the components as covariates in our analysis, the 
effect was actually stronger. Therefore, not adjusting our main analysis for 
population substructure is likely resulting in a downward bias of the true 
association. Fourth, the NFBC1966 cohort used for our controls consisted of 
relatively young individuals (31 years old). Given the mean age of our SCD 
cohort was 60 years old, it is likely some of our “controls” will go on to have an 
SCD event later in life, and by not excluding these individuals, we bias our 
estimates towards the null. Fifth, the Finnish population is quite homogenous and 
therefore our findings may not be able to be applicable to other populations, 
including other Europeans. Lastly, the strongest associations were seen in women 
and since women on average have lower rates of SCD, we have the least power to 
detect differences within this group. Nevertheless, our findings that female SCD 
victims with non-ischemic disease had the greatest association between longer QT 
interval and SCD risk were consistent between the various analyses performed, 
including both SNP association tests and Mendelian randomization. The 
directionality of our findings is consistent with our original hypothesis, which 
stated that the effect of longer QT interval will differ by underlying disease 
pathology and would be stronger in females than males. 
In conclusion, our study of autopsy-confirmed SCD victims provides 
consistent evidence to support the hypotheses that SCD risk factors, specifically 
lengthening of QT interval, may differ by both the underlying disease and sex.  
We found evidence of a genetic association in non-ischemic SCD victims, as well 
as a potentially causal association, between longer QT interval and SCD risk, with 
the largest genetic effect observed in female non-ischemic SCD individuals. SCD 
victims with underlying ischemic disease did not provide evidence for a genetic 
association, nor a causal association, between longer QT interval and SCD, 
regardless of sex. Our findings provide evidence that SCD risk factors, 




Figure 4.1 Multi-dimensional scaling (MDS) plot of Fingesture and 
NFBC1966 cohort samples 
A. Component 1 vs. Component 2 
 
 





















The plots A-E demonstrates strong genetic overlap between the Fingesture cohort 
(red) and the NFBC1966 cohort (blue). 





The top white panel represents the analysis including all SCA victims (2,282 
cases); the middle gray panel includes ischemic-only SCA victims (1,478 cases); 
and the bottom white panel includes only non-ischemic SCA victims (750 cases). 
The dots represent the odds ratio of the rs12143842 QT prolonging allele on SCA 
risk and the lines represent the 95% confidence intervals. Both sexes (black), 
females only (red), and males only (blue). Additional information found in Table 
4.6. 





The data points in the top plot represent the exponentiated GRSA estimates of QT 
interval on SCA (in log odds of SCA/SD of QT interval) and corresponding 95% 
confidence intervals. The top white panel represents the analysis including all 
SCA cases used in the MR analysis (1,168 cases); the middle gray panel includes 
ischemic-only SCA cases (611 cases); the bottom white panel includes only non- 
ischemic SCA cases (507 cases). Each panel includes analyses using: both sexes 
(black), females only (red), and males only (blue). Additional information found 
in Table 4.7. 
4.6 Tables 



















N, number of total cases 1168 358 574 572 825 
N, number of total controls 761 NA 422 2175 563 
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Table 4.2 Fingesture study characteristics. 
 







Mean age, year (SD) 61.23 (10.71) 60.65 (10.43) 63.84 (11.56) <0.001 
N, ischemic disease (%) 1,478 (64.8%) 1,245 (66.9%) 233 (55.5%) <0.001 
N, non-ischemic disease (%) 750 (32.8%) 579 (31.1%) 171 (40.7%) <0.001 
N, other (%) 54 (2.4%) 38 (2.0%) 16 (3.8%) 0.03 
BMI, kg/m2 (SD) 28.36 (6.61) 28.16 (6.23) 29.26 (8.10) 0.06 
Heart weight, g (SD) 493.60 (129.23) 509.60 (127.83) 421.40 (109.47) <0.001 
*P calculated for difference between men and women 
 
 








Mean Age (SD) 
 
N, Female 
NOS1AP SNP T 
Allele Frequency 
All Fingesture cases 2,282 61.23 (10.71) 420 0.264 
Female Fingesture cases 420 63.84 (11.56) 420 0.285 
Male Fingesture cases 1,862 60.65 (10.43) 0 0.259 
Ischemic Fingesture cases 1,478 64.10 (9.70) 233 0.258 
Non-ischemic Fingesture cases 750 56.22 (10.48) 171 0.276 
Fingesture cases, age 30-55 658 48.12 (5.99) 93 0.270 
Fingesture cases, age 56-85 1,604 66.70 (6.84) 322 0.262 
All NFBC1966 controls 3,561 31 (0) 1,920 0.242 
Female NFBC1966 controls 1,920 31 (0) 1,920 0.244 
Male NFBC1966 controls 1,641 31 (0) 0 0.240 
Table 4.4 Multi-dimensional scaling (MDS) regression results 
Covariate Beta SE P 
Sex -1.61 0.105 <0.001 
MDS Component 1 -0.296 0.328 0.36 
MDS Component 2 -0.231 0.288 0.42 
MDS Component 3 0.477 0.189 0.011 
MDS Component 4 -0.265 0.292 0.37 
MDS Component 5 0.099 0.269 0.71 
MDS Component 6 0.147 0.245 0.55 
MDS Component 7 0.316 0.102 0.002 
MDS Component 8 0.009 0.210 0.97 
MDS Component 9 -0.002 0.197 0.99 
MDS Component 10 0.001 0.194 0.99 
*Components were re-scaled by mulitiplying by 100 before regression to avoid numerical errors in R 
 
Table 4.5 Multi-dimensional scaling (MDS) regression results for rs12143842 
Covariates used in model Beta SE P Variance Explained 
Sex 0.211 0.083 0.011 0.101 
Sex + MDS Components 1-10 0.227 0.084 0.007 0.108 





























P for ischemic/ 
non-ischemic 
difference 
All cases/population controls 2282/3561 0.133 0.047 0.005  
ischemic cases/population controls 1478/3561 0.086 0.055 0.11  0.15 non-ischemic cases/population controls 750/3561 0.203 0.067 0.003 
Other cases/population controls 54/3561 0.106 0.226 0.64  
 
 Males only 
Dataset cases/controls Beta SE P 
All cases/population controls 1862/1641 0.101 0.056 0.07 
ischemic cases/population controls 1245/1641 0.083 0.062 0.18 
non-ischemic cases/population controls 579/1641 0.160 0.080 0.045 




























All cases/population controls 420/1920 0.211 0.087 0.015 0.14 
ischemic cases/population controls 233/1920 0.100 0.114 0.39 0.86 
non-ischemic cases/population controls 171/1920 0.314 0.126 0.013 0.14 
Other cases/population controls 16/1920 0.649 0.377 0.09 0.015 































All cases/population controls 1168/761 57 0.352 [-0.191, 0.895] 0.20  
ischemic cases/population controls 611/761 57 -0.124 [-0.757, 0.510] 0.70  0.09 non-ischemic cases/population controls 507/761 57 0.671 [-0.003, 1.340] 0.05 
 











All cases/population controls 950/354 57 0.126 [-0.567, 0.820] 0.72 
ischemic cases/population controls 528/354 57 -0.083 [-0.881,0.716] 0.84 


























All cases/population controls 218/407 57 0.783 [-0.112, 1.680] 0.09 0.26 
ischemic cases/population controls 83/407 57 -0.224 [-1.530, 1.080] 0.74 0.86 
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